CA1284454C - Implantable gas-containing biosensor and method for measuring an analyte such as glucose - Google Patents
Implantable gas-containing biosensor and method for measuring an analyte such as glucoseInfo
- Publication number
- CA1284454C CA1284454C CA000516055A CA516055A CA1284454C CA 1284454 C CA1284454 C CA 1284454C CA 000516055 A CA000516055 A CA 000516055A CA 516055 A CA516055 A CA 516055A CA 1284454 C CA1284454 C CA 1284454C
- Authority
- CA
- Canada
- Prior art keywords
- oxygen
- analyte
- enzymatic reaction
- enzyme
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 65
- 239000008103 glucose Substances 0.000 title claims abstract description 65
- 239000012491 analyte Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 37
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 85
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 84
- 239000001301 oxygen Substances 0.000 claims abstract description 84
- 239000012528 membrane Substances 0.000 claims abstract description 69
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 66
- 102000004190 Enzymes Human genes 0.000 claims abstract description 57
- 108090000790 Enzymes Proteins 0.000 claims abstract description 57
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000126 substance Substances 0.000 claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims description 56
- 239000000047 product Substances 0.000 claims description 35
- 230000003287 optical effect Effects 0.000 claims description 20
- 230000006870 function Effects 0.000 claims description 19
- 239000000376 reactant Substances 0.000 claims description 19
- 108010015776 Glucose oxidase Proteins 0.000 claims description 18
- 235000019420 glucose oxidase Nutrition 0.000 claims description 18
- 239000004366 Glucose oxidase Substances 0.000 claims description 17
- 229940116332 glucose oxidase Drugs 0.000 claims description 17
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 16
- 239000007789 gas Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 239000012466 permeate Substances 0.000 claims description 9
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 9
- 229910052697 platinum Inorganic materials 0.000 claims description 8
- 239000000975 dye Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 description 46
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 239000000872 buffer Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 229920000260 silastic Polymers 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 9
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 9
- 229910001882 dioxygen Inorganic materials 0.000 description 9
- 229960000587 glutaral Drugs 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- -1 glucose Chemical class 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000011835 investigation Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000174 gluconic acid Substances 0.000 description 4
- 235000012208 gluconic acid Nutrition 0.000 description 4
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006238 glycylation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 238000002484 cyclic voltammetry Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000003969 polarography Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/817—Enzyme or microbe electrode
Abstract
Abstract of the Disclosure The present invention relates to a novel implantable biosensor and method for sensing products, such as hydrogen peroxide, generated from an enzymatic reaction between an analyte, like glucose, and an enzyme in the presence of oxygen. The novel implant-able biosensor is uniquely equipped with an enclosed chamber for containing oxygen and can be adapted for extracting oxygen from animal tissue adjacent the container. The reservoir of oxygen contained in the enclosed chamber is supplied to the enzymatic reaction from the side of the membrane opposite the enzyme.
The enclosed chamber is uniquely designed to be impermeable to substances, like liquid and cells, that possibly can interfere with the supply of the oxygen permeating through the membrane to the enzymatic reaction. Also, the implantable biosensor is designed to optically or electrically sense products generated from the enzymatic reaction which serve as a function of the analyte.
The enclosed chamber is uniquely designed to be impermeable to substances, like liquid and cells, that possibly can interfere with the supply of the oxygen permeating through the membrane to the enzymatic reaction. Also, the implantable biosensor is designed to optically or electrically sense products generated from the enzymatic reaction which serve as a function of the analyte.
Description
~213~
IMPLANTABLE GAS-CONTAINING BIOSENSOR AND
METHOD FOR MEASURING AN ANALYTE SUCH AS GLUCOSE
Back~round of the Disclosure Considerable-effort over the years has been devoted to discovering and improving analytical techniques for measuring biological substances in connection with medical and industrial applications.
An example of one such technique developed concerned polarographic electrode systems which were used to measure various biological materials ~ualitatively and quantitatively, and reference is made to my earlier U.S. Patent No. 2,913,386 describing such a polaro-graphic electrode system 40r the measurement of oxygen and the like. Reference is also made to my U.S.
Patent No. 3,380,905 which pertains to an improvement of the polarographic electrode system described in the above-mentioned U.S. patent.
About twenty years ago, enzyme-coupled electrodes were reported for the polarographic analysis of biological substances. For example, in my U.S.
Patent Nos. 3,539,455 and 2,913,386, membrane polaro-graphic electrode systems and methods were described A
~2~
for the rapid and accurate quantitative analysis of biological substances which theretofore could not be analyzed directly by polarographic methods. According to the description in my U.S. Patent No. 3,539,455, small molecular substances, such as glucose, were measured with a membrane polarographic electrode system. By use of cellulose or another membrane which is permeable to small molecules, such as glucose, but is impermeable to proteins, the membrane kept glucose oxidase enzyme on the side of the membrane with the anode for reaction with glucose. Therefore, for example, if a sample of blood were placed on the membrane side opposite the electrode, with an aqueous solution of the enzyme and oxygen on the electrode side o the membrane, the low molecular weight materials, such as glucose, passed from the blood samples through the membrane for enzymatic reaction adjacent the electrode. After a certain period of time a steady state was reached when the hydrogen peroxide concentration was directly proportional to the glucose concentration and the cell produced a current flow as a function of the amount of hydrogen peroxide being formed which served as an indication of the amount of glucose present. As disclosed in my article entitled "Electrode Systems for Continuous Monitoring In Cardiovascular Surgery", N.Y. Acad. of Sciences. 102:29-45 (1962), the C].ark oxygen electrode could be arranged so that it was sensitive to glucose 2~
by virtue of the fact that oxygen was consumed by enzymatic reaction in proportion to glucose content.
In such arrangement, the inner membrane was imperme-able to glùcose and the reaction was monitored by the drop in oxygen. My early membrane polarographic techniques for measurement of hydrogen peroxide were limited to the detection of small molecules which were capable of permeating the membrane for enzymatic reaction with an enzyme being contained on the electrode side of the membrane.
More recently, enzymatic techniques for measuring macromolecules, such as cholesterol have been made. Generally, the enzymatic methods combined two enzymes, cholesterol oxidase and cholesterol ester hydrolase, with colorimetric techniques. These colorimetric methods relied on enzymatic conversion of cholesterol or its esters to cho}estenone and hydrogen peroxide, and then on the reaction of the hydrogen peroxide with various compounds to produce measurable chromagens and fluorogens. In my U.S. Patent No.
4,040,908, I described a membrane polarographic anode suitable for measuring macromolecular substances, such as cholesterol, utilizing enzymatic reactions as a means to measure such macromolecular substances.
Additional techniques have been developed for measuring other biological substances in blood.
For instance, ethanol i5 currently measured in blood either directly or by breath sampling, by classical chemical, gas chromatographic and enzyme methods. One of the alcohol enzyme methods, for example, depends upon the polarographic measurement of hydrogen peroxide, while others depend upon the consumption of oxygen. In my more recent U.S. Patent No. 4,458,686, I disclosed the use of a polarographic electrode as a skin-contact analyzer to transcutaneously measure oxygen for determining blood substances, such as glucose or alcohol as well as measurement of alcohol going through the skin.
One of the most important biological sub-stances is glucose. This is true because glucose plays such a major role in the metabolism of the body in health and disease, particularly diabetes. For instance, mo~t of the scientific evidence to date indicates that it is the high blood and tissue glucose concentration per se, and not too low an insulin level or the presence of abnormal metabolites, such as hydroxybutyric acid and the like, which causes the organ damage in the various forms of diabetes mellitus. This damage may be caused by glycylation of many of the tens of thousands of proteins in the body.
Such glycylation is reflected by the glucose-hemoglobin AlC level in the blood, a substance commonly measured to give a time-integrated level for blood glucose. Since all enzymes are proteins, the high glucose level probably impairs the catalytic functions in every part of the body. Typical serious damage _L~ j 4 related to diabetes is blindness, loss of limbs, cardiac and circulatory failure and death.
At present, insulin is administered either by injecting intermittently throughout the day to control blood glucose or, in a very small population of diabetics, by a programmable pump which injects insulin subcutaneously. This results in considerable, potentially dangerous, fluctuation in blood glucose depending upon the severity of the disease. In some forms of diabetes the Beta cells which make insulin are completely destroyed and the person becomes totally insulin dependent for survival.
In view of the above background, it would be desirable to have a device which is capable of con-tinuously sensing glucose in the blood of diabeticpatients so that the insulin or glucose can be more effectively administered and regulated. Extensive efforts heretofore have been directed toward developing an implantable glucose sensor having the capability of controlling an insulin pump or at least to provide a continuous signal reflecting blood glucose concentra-tions. However, it is widely believed that an im-planted enzyme-based glucose sensor cannot work or, if it does work, such a sensor would last at best for only a few days, after implantation in the blood or a body ¢avity. In Schichiri, M. et al: Glycaemic Control In Pancreatectomized Dogs With A Wearable Artificial Endocrine Pancreas, Diabetoloqia. 24:179-184 ~1983), it was reported that a glucose sensor wasimplanted and it lasted for six days after the date of in vivo implantation. Up to this point, such success even though limited has been considered remarkable.
Nevertheless, the limited operability of such sensors lead the scientific community to believe that implanted glucose oxidase type glucose sensors are not practical.
In support of such belief, a penumbra of reasons are given. For instance, it is generally thought that the enzyme, glucose oxidase, is too unstable to remain active for any period of time in a human at human body temperature. Furthermore, it is believed that glucose oxidase would be destroyed by bacteria or fungi. It is further believed that the electrodes' permeable membrane would be destroyed by tissue cells and enzymes or would become plugged as a result of large molecules, cellular debris and white and red blood cells collecting thereon. Additionally, it is thought that the amount of oxygen available necessary for the enzymatic reaction would be insufficient; or that co-enzymes would diffuse away from the enzyme through glucose permeable membranes; or that the platinum electrode surface would become plated, poisoned, inactivated or passivated thereby preventing reduction of the hydrogen peroxide generated; or that tissue response would interfere with glucose permeation through the membrane.
In summary, while there are a variety of devices and techniques available for the measurement of biological substances, new implantable devices and methods are needed for the measurement, administration and/or regulation of key biological substances, such as blood glucose and insulin. It would be especially beneficial if a satisfactory implantable device could be provided to aid in the control and alleviation of diabetes.
SummarY of the Invention In brief, the present invention seeks to alleviate the above discussed problems and short-comings of the present state of the art. This inven-tion is dixected to new and improved optical, elec-trical or other devices for sencing a product orreactant, such as hydrogen peroxide, derived from enzymatic reactiona between analytes and enzymes as a mea~ure of the amount of the analytes. This invention is predicated in part upon the discovery that problems heretofore associated with enzyme sensors can be overcome by providing a structure for an ample and/or steady supply of oxygen for enzymatic reaction at the sensor surface. The device of this invention is also uniquely suited for in vivo implantation and in measuring analytes, such as glucose, in undiluted, whole blood. It has been discovered that an enzyme and an electrode of this device when implanted does in fact remain active for as long as six months or more.
In view of the present state of the art, this is remarkable. In one preferred form of the invention, the amount or leve} of hydrogen peroxide is detected as a measure of the amount or level of glucose in the animal body. The types of animal fluid or tissue selected for implantation include both blood and non-blood sites such as intravascular, spinal fluid, peritoneal fluid, and extra and intracellular fluids.
In one embodiment of the present invention, the device comprises a gas permeable membrane having opposed sides, an enzyme on one side of the membrane for enzymatic reaction with the analyte in the presence of molecular oxygen to generate a product, a closed container for the molecular oxygen on the opposite side of the membrane to supply molecular oxygen through the membrane for the enzymatic reac-tion, and means for sensing the generated product or a reactant which functions as a measure of the analyte.
The present invention contemplates providing sensing devices predicated upon sensing a product or reactant involved in an oxygen-dependent enzymatic reaction and having the capability to provide to the enzymatic reaction from the container located on the side of the membrane opposite the enzyme a steady source of oxygen either extracted from the surrounding environment or derived independently of the surrounding environment. It is further contemplated that such a sensing device can be uniquely designed so that the container is adapted to generate oxygen which then can be supplied on demand to the enzymatic reaction. In other words, the enzymatic reaction determines the amount of oxygen necessary to convert the analyte to a product which ultimately is sensed. It should be appreciated, however, that the consumption of oxygen as a reactant supplied on demand, by a servo mechanism or other device, to the enzymatic reaction can also function as a measure for the analyte under investi-gation. It is still further contemplated that, sinceit has been discovered that the enzymatic reactions utilized by this invention are oxygen limiting, such a sensing device can be constructed so that the container provideY a constant supply of oxygen for the enzymatic reaction which is always in excess of the amount needed for the enzymatic reaction.
In a preferred embodiment, the device comprises an enclosed chamber adapted for containing oxygen comprising a wall structure def$ning a hollow interior and having an external surface wherein at least a portion of the external surface has the enzyme associated therewith for the enzymatic reaction, the wall structure being adapted for allowing molecular oxygen to permeate therethrough to supply molecular oxygen for the enzymatic reaction, an analyte perme-able membrane overlying the enzyme and connected to the chamber for allowing the analyte to permeate therethrough to supply the analyte for the enzymatic ~l2~S~
reaction, and means for sensing the product generated from the enzymatic reaction which functions as a measure of the analyte.
The invention is also directed to novel methods of sensing a product or reactant of an enzymatic reaction between an analyte and an enzyme in presence of oxygen as a measure of the analyte in vivo or in vitro. Such a method comprises providing a gas permeable membrane having opposed sides, providing an enzyme on one side of the membrane for enzymatic reaction with the analyte in presence of molecular oxygen to generate a product, providing a closed container for the molecular oxygen on the opposite side of the membrane to supply molecular oxygen through the membrane for the enzymatic reaction, and sensing the generated product or reactant which functions as a measure of the analyte.
The above features and advantages of the invention will be better understood with reference to the accompanying drawing~, detailed description and examples. It will also be understood that the par-ticular devices and methods embodying the invention are exemplary only and not to be regarded as a limi-tation of the invention.
Brief DescriPtion of the Drawings Reference is made to the accompanying drawings in which is shown illustxative embodiments of _;L-`t~
--ll--the invention from which its novel features and advantages will be apparent.
Fig. 1 is a cross section of one form of an electrical device which is illustrative of an embodi-ment of the invention;
Fig. 2 is a depiction of generated cyclic in vitro polarograms of changing glucose concentrations in a liquid sample, e.g., Gomori buffer, void of oxygen utilizing the electrical device described in Example l;
Fig. 3a is a depiction of generated cyclic in vitro polarograms of changing glucose concentra-tions in a liquid sample, e.g., Gomori buffer, utilizing an electroenzymatic glucose sensor of the present invention; and Fig. 3b is a depiction of cyclic in vitro polarograms of changing glucose concentrations in undiluted fresh whole goat blood utilizing the same sensor referred to in the description of Fig. 3a.
Detailed Description of the Invention By way of illustrating and providing a better appreciation of the present invention, the following detailed description is given concerning the methods of the invention.
By the term "animal tissue" as used herein, it is meant to include all animal tissues including body fluids and blood.
As used in this specification, "closed container" is meant to refer to a container that is impermeable to substances, such as liquids and cells, that might interfere with the ability of the container or membrane associated with the enzyme to supply oxygen to the enzymatic reaction. By the term "product" generated from the enzymatic reaction, it refers herein to the product produced from such a reaction, like hydrogen peroxide or gluconic acid or pyruvic acid, or products generated from the "product".
The term "reactant" is meant to include a substance involved directly or indirectly in the enzymatic reaction, such as oxygen, for instance. It should therefore be appreciated that the biosensor and methods of this invention can sense the products or reactant of the enzymatic reaction, or by-products derived from the generated products, which function as a measure of the analyte.
The term "analyte" refers herein to any material suitable for analysis with polarographic, potentiometric, optical or other techniques. An example of one of many other techniques is conducto-metric, e.g., glucose is not electrically conductive but gluconic acid can be so detected as a measure of the analyte. Further, hydrogen peroxide can be detected by electron spin resonance, and so forth.
Exemplary of analytes that can be detected according to the teachings of this invention include, for instance, glucose and lactate. The product generated, such as hydrogen peroxide, by the enzymatic reaction between an analyte and an enzyme in the presence of oxygen which can be sensed using known standard electrical or optical techniques serves as a measure of the analyte under investigation. For instance, hydrogen peroxide in an electrical system can generate an anodic current when subjected to a sufficient voltage, or, in an optical system, it can react with or be reduced to react with an optical substance to generate chromagens or fluorogens which then can be detected optically.
The present invention is especially directed to device~ for sensing hydrogen peroxide generated from an enzyme reaction with glucose or lactate in a liquid sample in the presence of oxygen as a measure of glucose or lactate. Alternatively, oxygen may be sensed as a measure of the analyte. The devices are especially suited for in vivo implantation and detecting such analytes in undiluted, whole blood.
The novel biosensors are uniquely designed to provide an independent source of oxygen fo_ the enzymatic reaction to overcome apparent oxygen deficiencies that otherwise arise in the liquid sample under investi-gation. In other words, it has been found thatproblems heretofore encountered in enzymatic electrode or optical structures are overcome by the inventive device. The devices of the present invention have been found ideally suitable for use or implantation in low oxyqen tension areas, such as the peritoneal cavity, and for measuring glucose therein.
Referring now to Fig. 1, it is a diagrammatic illustration of a typical device of the present invention and illustrates sensor 5 provided with an air space gas pocket 12 on the side of a gas permeable membrane 6a opposite the enzyme which functions as an independent reservoir of oxygen for supplying an enzymatic reaction. More particularly, Fig. 1 depicts a sensor 5 connected to an enclosed container or chamber 6 having top, bottom and opposed sides 6a, 6b, 6c, and 6d, respectively. It should be readily appreciated that, for purposes of the illustration in Fig. 1, top 6a of chamber 6 is the gas permeable membrane. Mounted on outside surface of side 6a of chamber 6 is an enzyme 7 in contact with an anode 8.
Preferably, anode 8 is platinum and spread or fanned across the top surface of side 6a of chamber 6. Anode 8 preferably is in the form of a grid or numerous wires (not shown) branching out over top 6a, the membrane, so that the oxygen can diffuse more readily around the anode. Anode 8 which extends into and through chamber 6 is covered in chamber 6 with an insulated wire 9, such as polytetrafluoroethylene commonly referred to under the trademark Teflon. The wire 9 can be situated outside of the chamber.
Overlying the enzyme 7 and anode 8 and connected to ~2~ i4 chamber 6 is an analyte permeable membrane 10. Fig. 1 depicts membrane 10 being sealed to chamber 6 by any suitable means well known to those versed in the art.
The analyte permeable membrane can be comprised of any suitable material, such a5 cellulose. Preferably, membrane 10 is permeable to small molecu}es, such as glucose and lactate, but impermeable to macromolecules, such as proteins and the like. Exemplary of other suitable membranes that may be employed with the sensors of the present invention are disclosed in Table 1 of Thevenot, D.R.: Problems In Adapting A
Glucose-Oxidase ElectroChemical Sensor Into An Implantable Glucose-Sensor Device, Diabetes Care.
5(3):184-189 (May-June 1982~.
Chamber 6 is preferably constructed out of material that is gas permeable and liquid impermeable. An ideal material employed having such characteristics is reinforced silastic, such as an organosilicone polymer, like Dow Corning subdermal implant No. 501-1, 0.007 in. thic~). To further illustrate the preferred use of silastic to formulate the chamber of this inven-tion, it has been discovered that upon implantation into an animal over a period of time, the chamber remained relatively free of liquid. This is quite a significant discovery especially in view of the fact that silastic is permeable to water vapor. It should be appreciated, however, that other materials having ~L~~
similar characteristics, such as polytetrafluoro-ethylene commonly referred to under the trademark Teflon, may be employed.
Although not shown in the Figs., it should be appreciated to those in the art that the sensors of the present invention may include a "third" membrane placed over anode 8 to separate enzyme 7 from anode 8.
This is commonly referred to as the "sandwich" concept which is well known in the art and exemplified in Clark, L.C., Jr. et al: Rapid Micromeasurement Of Lactate In Whole 3100d, Critical Care Medicine.
12(5):461-464 (May, 19841 and Clark, L.C., Jr, and Duggan, C.A.: Implanted Electroenzymatic Glucose Sensors, Diabetes Case. 5(3):174-180 (May-June 1982).
The "third" membrane may be formed of, for instance, cellulose acetate or the like. The advan-tages associated with such a membrane are at least twofold. First, such a membrane allows selective diffusion of the enzvme-generated product, such as hydrogen peroxide, to the anode where the peroxide is oxidized resulting in the current which functions as a measure of the enzyme substrate, e.g., glucose or lactate. Secondly, since there can be several poten-tially interfering substances, such as ascorbic acid and phenolic compounds like acetaminophen, present in the body, the employment of the "third" membrane provides a barrier to such interfering substances ~.`
_~L;~
reducing the possibility of inaccurate or incorrect measurements. A cellulose acetate membrane has been employed in the art to exclude interfering compounds.
In a further feature of the present inven-tion, the device is designed to extract oxygen from the environment surrounding the chamber. For instance, when the sensor is implanted, the closed container of the present invention preferably is adapted to extract oxygen from the animal tissue located adjacent thereto to provide a constant and self-sufficient supply of oxygen for the enzymatic reaction. As mentioned, the silastic material is ideally suited for this purpose.
In a further feature of the present inven-tion, incorporated into enclosed container or cha~ber 8 of the device i~ an oxygen transporting agent, such as a perfluorocarbon or derivative thereof, silicone oils or other organic oxygen solvents. In the case of a perfluorocarbon or derivative thereof, a perfluoro-cyclocarbon is preferred. Such compositions are well known in the art and an exemplary list of suitable perfluorocarbons and derivatives thereof can be found in my U.S. Patent Nos. 4,443,480 and 3,911,138.
The enzyme along with an emulsion comprising a perfluorocarbon or derivative thereof can also be included in chamber 6. In such a case, chamber 6 containing the enzyme should be adapted to permit the enzyme to permeate top 6a therethrough to supply the c~
enzyme for the enzymatic reaction. When the enzyme is incorporated into chamber 6 and top 6a, the membrane, modified for enzyme permeation, enzyme 7 need not be on the outer surface of top 6a, the membrane, as depicted in Fig. 1.
It is further envisaged by the biosensors of the present invention that they may contain audio or visual devices which can serve as a measure of the analyte under investigation and convey to, for instance, an implantee in the case of an implantable sensor, such information via audio or visual means, respectively. In the case of audio devices, such devices may be programmed to provide an audio sound all day or at certain times of the day which would reflect the concentration of, _or example, glucose in the blood. ~adio telemetry devices can be employed.
With respect to visual devices, these devices would be programmed to provide all day or intermittently, for instance, a light in which the intensity thereof would serve as a function of the analyte. The use of such audio or visual techniques are well known to those skilled in the art and can be adapted to be used in connection with the present invention for the purposes described above.
When an electrical sensor is employed, the voltage applied may be fixed, switched, cycled or pulsed. When the voltage applied i5 fixed, it may be applied in the range of about 0.5 to about 1.0 positive or negative volts for sensing the product generated, such as hydrogen peroxide, to detect the analyte or for detecting oxygen, respectively.
Preferably, the fixed voltage should be at about +0.6 or -0.6 volts for measuring the analyte or oxygen.
When the voltage applied is switched, i.e., switched between anodic and cathodic voltages over time for generating anodic and cathodic currents, respectively, it may be applied in a range of up to about 1.3 positive or negative volts for detecting the analyte or oxygen, respectively. Preferably, the switched voltage should be at about -0.6 volt~ when detecting oxygen and +0.6 volts when detecting the analyte.
When the voltage applied i5 cycled, the voltage may be applied in a loop starting, for example, at positi~e going to negative and back to positive in a range of from about +0.5 to -0.5 to +0.5 volts, and preferably from about +0.6 to -0.6 to +0.6 volts. In other words, the voltage applied is cycled over the appropriate range. The advantages to cycling the voltage are numerous. For instance, by cycling the applied voltage, it permits the molecular oxygen to be examined almost simultaneously with the analyte under investigation to ensure that a sufficient supply of A~
oxygen is available for the reaction. Additionally, it has been learned that the cycling technique pro-vides for a cleaner electrode, e.g., it reduces the amount of plating presently encountered on a platinum electrode. It also has been learned that cycling the voltage neutralizes the environment immediately surrounding the sensor. This is particularly advanta-geous since an anodic current generates hydrogen ions and a cathodic current generates hydroxyl ions. When the voltage is pulsed, the voltage is turned on intermittently in brief intervals, such as for example about ten seconds to about sixty seconds every five minutes or longer, for purposes of sensing a generated product, like hydrogen peroxide, ater a steady s~ate has been achieved around the sensor. It is believed, that the use of the pulsing technique results in higher currents and better measurements because of the steady state achieved. Such pulsing techniques are described in U.S. Patent No. 4,464,230.
In a further aspect of the invention, a two electrode or three electrode system may be utilized.
Although such systems are not shown, these systems are well known in the art. Generally speaking, the two electrode system is suitable for measuring analytes in aqueous solutions having high electrical conductivity whereas three electrode systems are suitable for measuring analytes in solution with low conductivity.
In either a two or three electrode system, it should be appreciated that the "reference" and "counter"
electrodes may be located remote from, near or in-cluded as part of the sensor. When the electrodes are included as part of the sensor, which is the preferred form, it is most preferred that the electrodes all be located on the same side of the membrane especially when analyzing analytes in low conductivity samples.
In addition to providing an electrical device for sensing hydrogen peroxide or a product produced therefrom, the present invention contemplates providing an optical sensor utilizing, for example, a dye in connection with monochromatic, dichromatic or multiple chromatic light which can be transmitted through an optical fiber and the light spectrum received with known instrumentation to reveal the analyte concentration of a liquid sample under investigation. In using a chromatic light sensor, the dye can be, for example, located on membrane 6a in contact with enzyme 7 for reacting with hydrogen peroxide or a product generated therefrom to generate a color which can be optically sensed and which functions as a measure of the analyte under investi-gation. In addition, as a result of enzymatic reac-tions, fluorescence and phosphorescence can occur.
Hence, by a suitable device containing an enzyme, a fluorescent or phosphorescent dye and the photo-activating product, i.e, hydrogen peroxide or a product derived therefrom, generated from the enzymatic reaction, one can detect an analyte concen-tration by measuring the amount of light emitted through the fiber optic by the fluorescence or phos-phorescent reaction between the hydrogen peroxide orproduct derived therefrom and the fluorescent or phosphorescent dye. Such dyes are known which fluoresce in presence of hydrogen peroxide. Further, the color of phenol red is pH dependent. It would change (red to yellow) as more gluconate is produced from glucose, and such a method could also be used.
In accordance with a further aspect of this invention and as aforementioned, the devices may be utilized in vitro or in vivo. When utilizing the device in vitro, the measurement should preferably be made in, for example, a suitable amount of a magnet-ically stirred buffer or whole blood in, for instance, a glass chamber jacketed with water circulating at about 37. Exemplary of buffers suitable for use include phosphate buffers, such as Gomori buffer which is well known and described in the art. A glucose measurement can be made directly in whole blood on the finger, from a finger cut, using a temperature compen-sated precalibrated sensor.
With respect to implantation, i.e., in vivo, of the devices in an animal includinq a human, any known technique not inconsistent with this invention may be employed. Exemplary of such a technique is described in Clark, L. C. et al: Theoretical And Practical Basis For Implantable Glucose Sensors With Special ReferenCe To The Peritoneum, Proceedings of the Symposium on ~iosensors. Los Angeles, Calif. A.R.
Potvin and Mr. Neuman (Eds.) Institute Of Electrical And Electronics Engineer (IEEE). New York , N.Y. pp.
69-74 (Sept. 15-17, 1984) and Clark, L. C. and Duggan, A.: Imp~anted Electroenzymatic Sensor, Diabetes Care. -5(3):174-180 (May-June 1982).
As to the site of implantation, the devices may be implanted in both blood and non-blood sites. Exemplary of non-blood sites include subcutaneous, intramuscular, epihepatic, intraperitoneal and brain sites, and most preferably intraperitoneal sites. With respect to the intraperitoneal sites, the sensor may be implanted in, on or near, but not limited to, the pancreas, liver, peritoneum, stomach, or intestines. Of course, it i5 contemplated herein, that when such devices are implanted, they can be adapted for use with insulin pumps or other related devices in vivo or in vitro in connection with diabetic patients. Exemplary of such use can be found in Albisser, A. M.: Insulin Delivery Systems: Do They Need a Glucose Sensor, Diabetes Case. 5(3):166-173 (May-June 1982) which is also incorporated in its entirety herein by reference.
With respect to enzyme 7, it is preferably located on the outer surface of side 6a of a chamber 6 A
~-2~
in contact with a platinum anode 8. The enzymes are preferably immobilized and stabilized thereon via glutaraldehyde treatment well known in the art. For example, after assembly of a sensor in accordance with the teachings of this invention, it is placed in the vapor of glutaraldehyde in a glass chamber overnight.
The vapor is generated by a layer of 25% glutaralde-hyde in the bottom of the chamber. This treatment, which i5 conducted at room temperature, serves to insolubilize and/or stabilize the enzyme, such as glucose oxidase, and to sterilize the sensor.
Following treatment, it preferably is stored in 70 percent ethanol in the cold, unti} u6ed. It has been found that traces of residual glutaraldehyde can be detected by cyclic voltammetry. In this way, it is possible to be sure that the excess glutaraldehyde has been removed. Other sensitive tests for traces of glutaraldehyde, such as those used after re-use sterilization of clinical dialyzers, are used occasionally. When glucose is being measured, glucose oxidase derived from sources, such as Penicillin notatum or AsPerqillus niqer, may be used.
In view of the above enzymatic reaction, it is obvious that a number of enzymes in addition to glucose oxidase and lactate oxidase can be used in order to detect and measure numerous analytes in vivo or in vitro. The following table is an exemplary listing of many of the enzymes, their identifying a ~$ ~L
number, source and typical analytes with which they may react for measuring in accordance with the principles of this invention.
~2~
o ~ o g ~n ~ U ~ ~ V ~ 3 _ ~0 ~ ' ~~ C ~ ~ ~ X ~ ~ C
u ~ ' u ,o, ~O O g ~ ~ ,.
c ~ >". _ u oc u c o ~ O Ql ~ ~ ~ c ~ e >. ~ ~ ~ X X s ~ ~ C O ~ O ~ ~ ~
~ O u c U ~ O O c~ C _ -I tc, O 'e ~ ~ c x ~ e _ I I ~ I o U
:~ ~ Cl ~ ,e D X
~ .
.~
t~ E ~ Y
~ ~ O X
~ -. O
1~1 O E ~ E ~ O U ~J
8 ~ E _~
,C ~ ."."~_~ ~ .", C
U ~ ~ O ~ -1 11 C
C ~D - J . " ~ D -- U
o o, o ,D",~ o o u~ ~ 2 ~ ~,ca, L~ e ~, 3 D
~ _l ~~ U~ ~ , . , ~ ~ ~-7 ~ ~7 t-7 t ~ 1 1 r~ ~
~ _ ~ I N N
Z
D ~o n O ~ x Y
v OxO x _ r x o ~ ~o n ~ u ~ J
IMPLANTABLE GAS-CONTAINING BIOSENSOR AND
METHOD FOR MEASURING AN ANALYTE SUCH AS GLUCOSE
Back~round of the Disclosure Considerable-effort over the years has been devoted to discovering and improving analytical techniques for measuring biological substances in connection with medical and industrial applications.
An example of one such technique developed concerned polarographic electrode systems which were used to measure various biological materials ~ualitatively and quantitatively, and reference is made to my earlier U.S. Patent No. 2,913,386 describing such a polaro-graphic electrode system 40r the measurement of oxygen and the like. Reference is also made to my U.S.
Patent No. 3,380,905 which pertains to an improvement of the polarographic electrode system described in the above-mentioned U.S. patent.
About twenty years ago, enzyme-coupled electrodes were reported for the polarographic analysis of biological substances. For example, in my U.S.
Patent Nos. 3,539,455 and 2,913,386, membrane polaro-graphic electrode systems and methods were described A
~2~
for the rapid and accurate quantitative analysis of biological substances which theretofore could not be analyzed directly by polarographic methods. According to the description in my U.S. Patent No. 3,539,455, small molecular substances, such as glucose, were measured with a membrane polarographic electrode system. By use of cellulose or another membrane which is permeable to small molecules, such as glucose, but is impermeable to proteins, the membrane kept glucose oxidase enzyme on the side of the membrane with the anode for reaction with glucose. Therefore, for example, if a sample of blood were placed on the membrane side opposite the electrode, with an aqueous solution of the enzyme and oxygen on the electrode side o the membrane, the low molecular weight materials, such as glucose, passed from the blood samples through the membrane for enzymatic reaction adjacent the electrode. After a certain period of time a steady state was reached when the hydrogen peroxide concentration was directly proportional to the glucose concentration and the cell produced a current flow as a function of the amount of hydrogen peroxide being formed which served as an indication of the amount of glucose present. As disclosed in my article entitled "Electrode Systems for Continuous Monitoring In Cardiovascular Surgery", N.Y. Acad. of Sciences. 102:29-45 (1962), the C].ark oxygen electrode could be arranged so that it was sensitive to glucose 2~
by virtue of the fact that oxygen was consumed by enzymatic reaction in proportion to glucose content.
In such arrangement, the inner membrane was imperme-able to glùcose and the reaction was monitored by the drop in oxygen. My early membrane polarographic techniques for measurement of hydrogen peroxide were limited to the detection of small molecules which were capable of permeating the membrane for enzymatic reaction with an enzyme being contained on the electrode side of the membrane.
More recently, enzymatic techniques for measuring macromolecules, such as cholesterol have been made. Generally, the enzymatic methods combined two enzymes, cholesterol oxidase and cholesterol ester hydrolase, with colorimetric techniques. These colorimetric methods relied on enzymatic conversion of cholesterol or its esters to cho}estenone and hydrogen peroxide, and then on the reaction of the hydrogen peroxide with various compounds to produce measurable chromagens and fluorogens. In my U.S. Patent No.
4,040,908, I described a membrane polarographic anode suitable for measuring macromolecular substances, such as cholesterol, utilizing enzymatic reactions as a means to measure such macromolecular substances.
Additional techniques have been developed for measuring other biological substances in blood.
For instance, ethanol i5 currently measured in blood either directly or by breath sampling, by classical chemical, gas chromatographic and enzyme methods. One of the alcohol enzyme methods, for example, depends upon the polarographic measurement of hydrogen peroxide, while others depend upon the consumption of oxygen. In my more recent U.S. Patent No. 4,458,686, I disclosed the use of a polarographic electrode as a skin-contact analyzer to transcutaneously measure oxygen for determining blood substances, such as glucose or alcohol as well as measurement of alcohol going through the skin.
One of the most important biological sub-stances is glucose. This is true because glucose plays such a major role in the metabolism of the body in health and disease, particularly diabetes. For instance, mo~t of the scientific evidence to date indicates that it is the high blood and tissue glucose concentration per se, and not too low an insulin level or the presence of abnormal metabolites, such as hydroxybutyric acid and the like, which causes the organ damage in the various forms of diabetes mellitus. This damage may be caused by glycylation of many of the tens of thousands of proteins in the body.
Such glycylation is reflected by the glucose-hemoglobin AlC level in the blood, a substance commonly measured to give a time-integrated level for blood glucose. Since all enzymes are proteins, the high glucose level probably impairs the catalytic functions in every part of the body. Typical serious damage _L~ j 4 related to diabetes is blindness, loss of limbs, cardiac and circulatory failure and death.
At present, insulin is administered either by injecting intermittently throughout the day to control blood glucose or, in a very small population of diabetics, by a programmable pump which injects insulin subcutaneously. This results in considerable, potentially dangerous, fluctuation in blood glucose depending upon the severity of the disease. In some forms of diabetes the Beta cells which make insulin are completely destroyed and the person becomes totally insulin dependent for survival.
In view of the above background, it would be desirable to have a device which is capable of con-tinuously sensing glucose in the blood of diabeticpatients so that the insulin or glucose can be more effectively administered and regulated. Extensive efforts heretofore have been directed toward developing an implantable glucose sensor having the capability of controlling an insulin pump or at least to provide a continuous signal reflecting blood glucose concentra-tions. However, it is widely believed that an im-planted enzyme-based glucose sensor cannot work or, if it does work, such a sensor would last at best for only a few days, after implantation in the blood or a body ¢avity. In Schichiri, M. et al: Glycaemic Control In Pancreatectomized Dogs With A Wearable Artificial Endocrine Pancreas, Diabetoloqia. 24:179-184 ~1983), it was reported that a glucose sensor wasimplanted and it lasted for six days after the date of in vivo implantation. Up to this point, such success even though limited has been considered remarkable.
Nevertheless, the limited operability of such sensors lead the scientific community to believe that implanted glucose oxidase type glucose sensors are not practical.
In support of such belief, a penumbra of reasons are given. For instance, it is generally thought that the enzyme, glucose oxidase, is too unstable to remain active for any period of time in a human at human body temperature. Furthermore, it is believed that glucose oxidase would be destroyed by bacteria or fungi. It is further believed that the electrodes' permeable membrane would be destroyed by tissue cells and enzymes or would become plugged as a result of large molecules, cellular debris and white and red blood cells collecting thereon. Additionally, it is thought that the amount of oxygen available necessary for the enzymatic reaction would be insufficient; or that co-enzymes would diffuse away from the enzyme through glucose permeable membranes; or that the platinum electrode surface would become plated, poisoned, inactivated or passivated thereby preventing reduction of the hydrogen peroxide generated; or that tissue response would interfere with glucose permeation through the membrane.
In summary, while there are a variety of devices and techniques available for the measurement of biological substances, new implantable devices and methods are needed for the measurement, administration and/or regulation of key biological substances, such as blood glucose and insulin. It would be especially beneficial if a satisfactory implantable device could be provided to aid in the control and alleviation of diabetes.
SummarY of the Invention In brief, the present invention seeks to alleviate the above discussed problems and short-comings of the present state of the art. This inven-tion is dixected to new and improved optical, elec-trical or other devices for sencing a product orreactant, such as hydrogen peroxide, derived from enzymatic reactiona between analytes and enzymes as a mea~ure of the amount of the analytes. This invention is predicated in part upon the discovery that problems heretofore associated with enzyme sensors can be overcome by providing a structure for an ample and/or steady supply of oxygen for enzymatic reaction at the sensor surface. The device of this invention is also uniquely suited for in vivo implantation and in measuring analytes, such as glucose, in undiluted, whole blood. It has been discovered that an enzyme and an electrode of this device when implanted does in fact remain active for as long as six months or more.
In view of the present state of the art, this is remarkable. In one preferred form of the invention, the amount or leve} of hydrogen peroxide is detected as a measure of the amount or level of glucose in the animal body. The types of animal fluid or tissue selected for implantation include both blood and non-blood sites such as intravascular, spinal fluid, peritoneal fluid, and extra and intracellular fluids.
In one embodiment of the present invention, the device comprises a gas permeable membrane having opposed sides, an enzyme on one side of the membrane for enzymatic reaction with the analyte in the presence of molecular oxygen to generate a product, a closed container for the molecular oxygen on the opposite side of the membrane to supply molecular oxygen through the membrane for the enzymatic reac-tion, and means for sensing the generated product or a reactant which functions as a measure of the analyte.
The present invention contemplates providing sensing devices predicated upon sensing a product or reactant involved in an oxygen-dependent enzymatic reaction and having the capability to provide to the enzymatic reaction from the container located on the side of the membrane opposite the enzyme a steady source of oxygen either extracted from the surrounding environment or derived independently of the surrounding environment. It is further contemplated that such a sensing device can be uniquely designed so that the container is adapted to generate oxygen which then can be supplied on demand to the enzymatic reaction. In other words, the enzymatic reaction determines the amount of oxygen necessary to convert the analyte to a product which ultimately is sensed. It should be appreciated, however, that the consumption of oxygen as a reactant supplied on demand, by a servo mechanism or other device, to the enzymatic reaction can also function as a measure for the analyte under investi-gation. It is still further contemplated that, sinceit has been discovered that the enzymatic reactions utilized by this invention are oxygen limiting, such a sensing device can be constructed so that the container provideY a constant supply of oxygen for the enzymatic reaction which is always in excess of the amount needed for the enzymatic reaction.
In a preferred embodiment, the device comprises an enclosed chamber adapted for containing oxygen comprising a wall structure def$ning a hollow interior and having an external surface wherein at least a portion of the external surface has the enzyme associated therewith for the enzymatic reaction, the wall structure being adapted for allowing molecular oxygen to permeate therethrough to supply molecular oxygen for the enzymatic reaction, an analyte perme-able membrane overlying the enzyme and connected to the chamber for allowing the analyte to permeate therethrough to supply the analyte for the enzymatic ~l2~S~
reaction, and means for sensing the product generated from the enzymatic reaction which functions as a measure of the analyte.
The invention is also directed to novel methods of sensing a product or reactant of an enzymatic reaction between an analyte and an enzyme in presence of oxygen as a measure of the analyte in vivo or in vitro. Such a method comprises providing a gas permeable membrane having opposed sides, providing an enzyme on one side of the membrane for enzymatic reaction with the analyte in presence of molecular oxygen to generate a product, providing a closed container for the molecular oxygen on the opposite side of the membrane to supply molecular oxygen through the membrane for the enzymatic reaction, and sensing the generated product or reactant which functions as a measure of the analyte.
The above features and advantages of the invention will be better understood with reference to the accompanying drawing~, detailed description and examples. It will also be understood that the par-ticular devices and methods embodying the invention are exemplary only and not to be regarded as a limi-tation of the invention.
Brief DescriPtion of the Drawings Reference is made to the accompanying drawings in which is shown illustxative embodiments of _;L-`t~
--ll--the invention from which its novel features and advantages will be apparent.
Fig. 1 is a cross section of one form of an electrical device which is illustrative of an embodi-ment of the invention;
Fig. 2 is a depiction of generated cyclic in vitro polarograms of changing glucose concentrations in a liquid sample, e.g., Gomori buffer, void of oxygen utilizing the electrical device described in Example l;
Fig. 3a is a depiction of generated cyclic in vitro polarograms of changing glucose concentra-tions in a liquid sample, e.g., Gomori buffer, utilizing an electroenzymatic glucose sensor of the present invention; and Fig. 3b is a depiction of cyclic in vitro polarograms of changing glucose concentrations in undiluted fresh whole goat blood utilizing the same sensor referred to in the description of Fig. 3a.
Detailed Description of the Invention By way of illustrating and providing a better appreciation of the present invention, the following detailed description is given concerning the methods of the invention.
By the term "animal tissue" as used herein, it is meant to include all animal tissues including body fluids and blood.
As used in this specification, "closed container" is meant to refer to a container that is impermeable to substances, such as liquids and cells, that might interfere with the ability of the container or membrane associated with the enzyme to supply oxygen to the enzymatic reaction. By the term "product" generated from the enzymatic reaction, it refers herein to the product produced from such a reaction, like hydrogen peroxide or gluconic acid or pyruvic acid, or products generated from the "product".
The term "reactant" is meant to include a substance involved directly or indirectly in the enzymatic reaction, such as oxygen, for instance. It should therefore be appreciated that the biosensor and methods of this invention can sense the products or reactant of the enzymatic reaction, or by-products derived from the generated products, which function as a measure of the analyte.
The term "analyte" refers herein to any material suitable for analysis with polarographic, potentiometric, optical or other techniques. An example of one of many other techniques is conducto-metric, e.g., glucose is not electrically conductive but gluconic acid can be so detected as a measure of the analyte. Further, hydrogen peroxide can be detected by electron spin resonance, and so forth.
Exemplary of analytes that can be detected according to the teachings of this invention include, for instance, glucose and lactate. The product generated, such as hydrogen peroxide, by the enzymatic reaction between an analyte and an enzyme in the presence of oxygen which can be sensed using known standard electrical or optical techniques serves as a measure of the analyte under investigation. For instance, hydrogen peroxide in an electrical system can generate an anodic current when subjected to a sufficient voltage, or, in an optical system, it can react with or be reduced to react with an optical substance to generate chromagens or fluorogens which then can be detected optically.
The present invention is especially directed to device~ for sensing hydrogen peroxide generated from an enzyme reaction with glucose or lactate in a liquid sample in the presence of oxygen as a measure of glucose or lactate. Alternatively, oxygen may be sensed as a measure of the analyte. The devices are especially suited for in vivo implantation and detecting such analytes in undiluted, whole blood.
The novel biosensors are uniquely designed to provide an independent source of oxygen fo_ the enzymatic reaction to overcome apparent oxygen deficiencies that otherwise arise in the liquid sample under investi-gation. In other words, it has been found thatproblems heretofore encountered in enzymatic electrode or optical structures are overcome by the inventive device. The devices of the present invention have been found ideally suitable for use or implantation in low oxyqen tension areas, such as the peritoneal cavity, and for measuring glucose therein.
Referring now to Fig. 1, it is a diagrammatic illustration of a typical device of the present invention and illustrates sensor 5 provided with an air space gas pocket 12 on the side of a gas permeable membrane 6a opposite the enzyme which functions as an independent reservoir of oxygen for supplying an enzymatic reaction. More particularly, Fig. 1 depicts a sensor 5 connected to an enclosed container or chamber 6 having top, bottom and opposed sides 6a, 6b, 6c, and 6d, respectively. It should be readily appreciated that, for purposes of the illustration in Fig. 1, top 6a of chamber 6 is the gas permeable membrane. Mounted on outside surface of side 6a of chamber 6 is an enzyme 7 in contact with an anode 8.
Preferably, anode 8 is platinum and spread or fanned across the top surface of side 6a of chamber 6. Anode 8 preferably is in the form of a grid or numerous wires (not shown) branching out over top 6a, the membrane, so that the oxygen can diffuse more readily around the anode. Anode 8 which extends into and through chamber 6 is covered in chamber 6 with an insulated wire 9, such as polytetrafluoroethylene commonly referred to under the trademark Teflon. The wire 9 can be situated outside of the chamber.
Overlying the enzyme 7 and anode 8 and connected to ~2~ i4 chamber 6 is an analyte permeable membrane 10. Fig. 1 depicts membrane 10 being sealed to chamber 6 by any suitable means well known to those versed in the art.
The analyte permeable membrane can be comprised of any suitable material, such a5 cellulose. Preferably, membrane 10 is permeable to small molecu}es, such as glucose and lactate, but impermeable to macromolecules, such as proteins and the like. Exemplary of other suitable membranes that may be employed with the sensors of the present invention are disclosed in Table 1 of Thevenot, D.R.: Problems In Adapting A
Glucose-Oxidase ElectroChemical Sensor Into An Implantable Glucose-Sensor Device, Diabetes Care.
5(3):184-189 (May-June 1982~.
Chamber 6 is preferably constructed out of material that is gas permeable and liquid impermeable. An ideal material employed having such characteristics is reinforced silastic, such as an organosilicone polymer, like Dow Corning subdermal implant No. 501-1, 0.007 in. thic~). To further illustrate the preferred use of silastic to formulate the chamber of this inven-tion, it has been discovered that upon implantation into an animal over a period of time, the chamber remained relatively free of liquid. This is quite a significant discovery especially in view of the fact that silastic is permeable to water vapor. It should be appreciated, however, that other materials having ~L~~
similar characteristics, such as polytetrafluoro-ethylene commonly referred to under the trademark Teflon, may be employed.
Although not shown in the Figs., it should be appreciated to those in the art that the sensors of the present invention may include a "third" membrane placed over anode 8 to separate enzyme 7 from anode 8.
This is commonly referred to as the "sandwich" concept which is well known in the art and exemplified in Clark, L.C., Jr. et al: Rapid Micromeasurement Of Lactate In Whole 3100d, Critical Care Medicine.
12(5):461-464 (May, 19841 and Clark, L.C., Jr, and Duggan, C.A.: Implanted Electroenzymatic Glucose Sensors, Diabetes Case. 5(3):174-180 (May-June 1982).
The "third" membrane may be formed of, for instance, cellulose acetate or the like. The advan-tages associated with such a membrane are at least twofold. First, such a membrane allows selective diffusion of the enzvme-generated product, such as hydrogen peroxide, to the anode where the peroxide is oxidized resulting in the current which functions as a measure of the enzyme substrate, e.g., glucose or lactate. Secondly, since there can be several poten-tially interfering substances, such as ascorbic acid and phenolic compounds like acetaminophen, present in the body, the employment of the "third" membrane provides a barrier to such interfering substances ~.`
_~L;~
reducing the possibility of inaccurate or incorrect measurements. A cellulose acetate membrane has been employed in the art to exclude interfering compounds.
In a further feature of the present inven-tion, the device is designed to extract oxygen from the environment surrounding the chamber. For instance, when the sensor is implanted, the closed container of the present invention preferably is adapted to extract oxygen from the animal tissue located adjacent thereto to provide a constant and self-sufficient supply of oxygen for the enzymatic reaction. As mentioned, the silastic material is ideally suited for this purpose.
In a further feature of the present inven-tion, incorporated into enclosed container or cha~ber 8 of the device i~ an oxygen transporting agent, such as a perfluorocarbon or derivative thereof, silicone oils or other organic oxygen solvents. In the case of a perfluorocarbon or derivative thereof, a perfluoro-cyclocarbon is preferred. Such compositions are well known in the art and an exemplary list of suitable perfluorocarbons and derivatives thereof can be found in my U.S. Patent Nos. 4,443,480 and 3,911,138.
The enzyme along with an emulsion comprising a perfluorocarbon or derivative thereof can also be included in chamber 6. In such a case, chamber 6 containing the enzyme should be adapted to permit the enzyme to permeate top 6a therethrough to supply the c~
enzyme for the enzymatic reaction. When the enzyme is incorporated into chamber 6 and top 6a, the membrane, modified for enzyme permeation, enzyme 7 need not be on the outer surface of top 6a, the membrane, as depicted in Fig. 1.
It is further envisaged by the biosensors of the present invention that they may contain audio or visual devices which can serve as a measure of the analyte under investigation and convey to, for instance, an implantee in the case of an implantable sensor, such information via audio or visual means, respectively. In the case of audio devices, such devices may be programmed to provide an audio sound all day or at certain times of the day which would reflect the concentration of, _or example, glucose in the blood. ~adio telemetry devices can be employed.
With respect to visual devices, these devices would be programmed to provide all day or intermittently, for instance, a light in which the intensity thereof would serve as a function of the analyte. The use of such audio or visual techniques are well known to those skilled in the art and can be adapted to be used in connection with the present invention for the purposes described above.
When an electrical sensor is employed, the voltage applied may be fixed, switched, cycled or pulsed. When the voltage applied i5 fixed, it may be applied in the range of about 0.5 to about 1.0 positive or negative volts for sensing the product generated, such as hydrogen peroxide, to detect the analyte or for detecting oxygen, respectively.
Preferably, the fixed voltage should be at about +0.6 or -0.6 volts for measuring the analyte or oxygen.
When the voltage applied is switched, i.e., switched between anodic and cathodic voltages over time for generating anodic and cathodic currents, respectively, it may be applied in a range of up to about 1.3 positive or negative volts for detecting the analyte or oxygen, respectively. Preferably, the switched voltage should be at about -0.6 volt~ when detecting oxygen and +0.6 volts when detecting the analyte.
When the voltage applied i5 cycled, the voltage may be applied in a loop starting, for example, at positi~e going to negative and back to positive in a range of from about +0.5 to -0.5 to +0.5 volts, and preferably from about +0.6 to -0.6 to +0.6 volts. In other words, the voltage applied is cycled over the appropriate range. The advantages to cycling the voltage are numerous. For instance, by cycling the applied voltage, it permits the molecular oxygen to be examined almost simultaneously with the analyte under investigation to ensure that a sufficient supply of A~
oxygen is available for the reaction. Additionally, it has been learned that the cycling technique pro-vides for a cleaner electrode, e.g., it reduces the amount of plating presently encountered on a platinum electrode. It also has been learned that cycling the voltage neutralizes the environment immediately surrounding the sensor. This is particularly advanta-geous since an anodic current generates hydrogen ions and a cathodic current generates hydroxyl ions. When the voltage is pulsed, the voltage is turned on intermittently in brief intervals, such as for example about ten seconds to about sixty seconds every five minutes or longer, for purposes of sensing a generated product, like hydrogen peroxide, ater a steady s~ate has been achieved around the sensor. It is believed, that the use of the pulsing technique results in higher currents and better measurements because of the steady state achieved. Such pulsing techniques are described in U.S. Patent No. 4,464,230.
In a further aspect of the invention, a two electrode or three electrode system may be utilized.
Although such systems are not shown, these systems are well known in the art. Generally speaking, the two electrode system is suitable for measuring analytes in aqueous solutions having high electrical conductivity whereas three electrode systems are suitable for measuring analytes in solution with low conductivity.
In either a two or three electrode system, it should be appreciated that the "reference" and "counter"
electrodes may be located remote from, near or in-cluded as part of the sensor. When the electrodes are included as part of the sensor, which is the preferred form, it is most preferred that the electrodes all be located on the same side of the membrane especially when analyzing analytes in low conductivity samples.
In addition to providing an electrical device for sensing hydrogen peroxide or a product produced therefrom, the present invention contemplates providing an optical sensor utilizing, for example, a dye in connection with monochromatic, dichromatic or multiple chromatic light which can be transmitted through an optical fiber and the light spectrum received with known instrumentation to reveal the analyte concentration of a liquid sample under investigation. In using a chromatic light sensor, the dye can be, for example, located on membrane 6a in contact with enzyme 7 for reacting with hydrogen peroxide or a product generated therefrom to generate a color which can be optically sensed and which functions as a measure of the analyte under investi-gation. In addition, as a result of enzymatic reac-tions, fluorescence and phosphorescence can occur.
Hence, by a suitable device containing an enzyme, a fluorescent or phosphorescent dye and the photo-activating product, i.e, hydrogen peroxide or a product derived therefrom, generated from the enzymatic reaction, one can detect an analyte concen-tration by measuring the amount of light emitted through the fiber optic by the fluorescence or phos-phorescent reaction between the hydrogen peroxide orproduct derived therefrom and the fluorescent or phosphorescent dye. Such dyes are known which fluoresce in presence of hydrogen peroxide. Further, the color of phenol red is pH dependent. It would change (red to yellow) as more gluconate is produced from glucose, and such a method could also be used.
In accordance with a further aspect of this invention and as aforementioned, the devices may be utilized in vitro or in vivo. When utilizing the device in vitro, the measurement should preferably be made in, for example, a suitable amount of a magnet-ically stirred buffer or whole blood in, for instance, a glass chamber jacketed with water circulating at about 37. Exemplary of buffers suitable for use include phosphate buffers, such as Gomori buffer which is well known and described in the art. A glucose measurement can be made directly in whole blood on the finger, from a finger cut, using a temperature compen-sated precalibrated sensor.
With respect to implantation, i.e., in vivo, of the devices in an animal includinq a human, any known technique not inconsistent with this invention may be employed. Exemplary of such a technique is described in Clark, L. C. et al: Theoretical And Practical Basis For Implantable Glucose Sensors With Special ReferenCe To The Peritoneum, Proceedings of the Symposium on ~iosensors. Los Angeles, Calif. A.R.
Potvin and Mr. Neuman (Eds.) Institute Of Electrical And Electronics Engineer (IEEE). New York , N.Y. pp.
69-74 (Sept. 15-17, 1984) and Clark, L. C. and Duggan, A.: Imp~anted Electroenzymatic Sensor, Diabetes Care. -5(3):174-180 (May-June 1982).
As to the site of implantation, the devices may be implanted in both blood and non-blood sites. Exemplary of non-blood sites include subcutaneous, intramuscular, epihepatic, intraperitoneal and brain sites, and most preferably intraperitoneal sites. With respect to the intraperitoneal sites, the sensor may be implanted in, on or near, but not limited to, the pancreas, liver, peritoneum, stomach, or intestines. Of course, it i5 contemplated herein, that when such devices are implanted, they can be adapted for use with insulin pumps or other related devices in vivo or in vitro in connection with diabetic patients. Exemplary of such use can be found in Albisser, A. M.: Insulin Delivery Systems: Do They Need a Glucose Sensor, Diabetes Case. 5(3):166-173 (May-June 1982) which is also incorporated in its entirety herein by reference.
With respect to enzyme 7, it is preferably located on the outer surface of side 6a of a chamber 6 A
~-2~
in contact with a platinum anode 8. The enzymes are preferably immobilized and stabilized thereon via glutaraldehyde treatment well known in the art. For example, after assembly of a sensor in accordance with the teachings of this invention, it is placed in the vapor of glutaraldehyde in a glass chamber overnight.
The vapor is generated by a layer of 25% glutaralde-hyde in the bottom of the chamber. This treatment, which i5 conducted at room temperature, serves to insolubilize and/or stabilize the enzyme, such as glucose oxidase, and to sterilize the sensor.
Following treatment, it preferably is stored in 70 percent ethanol in the cold, unti} u6ed. It has been found that traces of residual glutaraldehyde can be detected by cyclic voltammetry. In this way, it is possible to be sure that the excess glutaraldehyde has been removed. Other sensitive tests for traces of glutaraldehyde, such as those used after re-use sterilization of clinical dialyzers, are used occasionally. When glucose is being measured, glucose oxidase derived from sources, such as Penicillin notatum or AsPerqillus niqer, may be used.
In view of the above enzymatic reaction, it is obvious that a number of enzymes in addition to glucose oxidase and lactate oxidase can be used in order to detect and measure numerous analytes in vivo or in vitro. The following table is an exemplary listing of many of the enzymes, their identifying a ~$ ~L
number, source and typical analytes with which they may react for measuring in accordance with the principles of this invention.
~2~
o ~ o g ~n ~ U ~ ~ V ~ 3 _ ~0 ~ ' ~~ C ~ ~ ~ X ~ ~ C
u ~ ' u ,o, ~O O g ~ ~ ,.
c ~ >". _ u oc u c o ~ O Ql ~ ~ ~ c ~ e >. ~ ~ ~ X X s ~ ~ C O ~ O ~ ~ ~
~ O u c U ~ O O c~ C _ -I tc, O 'e ~ ~ c x ~ e _ I I ~ I o U
:~ ~ Cl ~ ,e D X
~ .
.~
t~ E ~ Y
~ ~ O X
~ -. O
1~1 O E ~ E ~ O U ~J
8 ~ E _~
,C ~ ."."~_~ ~ .", C
U ~ ~ O ~ -1 11 C
C ~D - J . " ~ D -- U
o o, o ,D",~ o o u~ ~ 2 ~ ~,ca, L~ e ~, 3 D
~ _l ~~ U~ ~ , . , ~ ~ ~-7 ~ ~7 t-7 t ~ 1 1 r~ ~
~ _ ~ I N N
Z
D ~o n O ~ x Y
v OxO x _ r x o ~ ~o n ~ u ~ J
3 J ': X
1~ =c~ = 2 , .,~ ~1 0 ~ o _ x ~ C ~ C c E ~ c o ~c ~ q x ~ ~ c cJ o u ~ ~ o O ~ a 3 ~ q o ~ ~ `X , ~ ~a ~ E ~ ~ ~ o e u O~ ~ O J Z t~ N ~ ~ E ~:1 0 Cl~
,~ ~U'0 o ~ - ~ o 9 U t~ o o'~ C O 3 ~
~ ~ ~ 8 ~ c c al ~ ~ ~ _, ~ ~ ~ ~r u~ ~ ~
, . , ,, ~ ~ , . _, , ~ ,o N C C
~ o x ~ ~ o e ~ o _ _ o ,' ~ , ~
.. .. ~
, u Z
C C ~ ~ o o C ..
U ~ C ~ U
."
~ ~ C ~ ~ ~ ~ ~ o o ~. o ~ ~ .. ~ ~"
~ c . . ~ o u u o ~ ~ ~ ~ ~ ~ 8 ~ ~ o Q :~ ~ ~ U
E G~ - ~ _ c 3` 31 X U I t~ E O a~
I Q, ~ V I I I I ~_ ¢ I ' I ~- I
z ~n la C n~ o Q ~ c~-l `' z ~ U z 2, ~ ~:
o C U ~o J tO ~ ~ U L~ ~
o ~ o ~ 0 a~ t`~ o N ~
Z _ ~
~o ~ 'U ~ 0 N 3 ~ o x ~ ~ ~
,. ,. ~ o o ~ o ~
S ~ ~ U C o ¢ U
It is also contemplated herein to incorpo-rate into, on or near the enclosed chamber 6, an electrolytic device or means for generating oxygen independent of the environment adjacent the device for independently generating or replenishing the reservoir of oxygen in the chamber. Such a device or means may be a small battery (not shown) attached on, near or inside chamber 6 for generating oxygen inside the chamber, or an oxygen generating cell ~not depicted) comprising phosphoric acid which becomes exposed to electrolyzed water from dissolved water vapor inside chamber 6 to produce oxygen. Oxygen from the electrolysis diffuses toward the sensor while hydrogen is preferred to difuse away from the sensor towards the body arrangeable by design of the electrolyte cell in the drum.
An electroenzymatic glucose sensor and an exemplary use thereof in accordance with the present invention will now be further illustrated by reference to the following examples.
ExamPle 1 A typical electroenzymatic sensor in accor-dance with this invention has been prepared as follows.
The drum was prepared from a piece of Dow Corning silastic tubing 0.1875 inches I.D. X 0.3125 inches O.D. A piece of about one centimeter was cut from this tubing and then on each end of the tubing was cemented to silastic sheeting using Dow Corning s~
silastic medical adhesive silicone type catalog No.
891 g}ue. The silastic sheeting or membrane was made by the Dow Corning Company and a one centimeter diameter circle of 0.010 inch thick material was cut.
The drum head was placed on both ends of the silastic tubing to form an enclosed drum. The wire used was MedWire Corp. platinum-iridium consisting of 9 strands of 0.0011 inch wire insulated with Teflon. A distance of about five millimeters of this wire's insulation was cut exposing the 9 strands of wire which were spread out across the surface of the drum. The wire was then put in 0.025 inches I.D. x 0.047 inches O.D.
silastic tubing and fastened to the edge of the tubing using silk thread. Then over the end of the elec-trode, where the platinum iridium wire had been spreadout, was placed a piece of regenerated cellulose membrane which was porous to glucose. The type found most useful was that called Spectropor and this was tubing made for dialysis and was made by the ~Jiscos process. When inflated, dialyzer tubing obtained from Arthur H. Thomas Co., Philadelphia, PA which has catalog No. 3787-F45, one and a quarter inch in diameter was used. Such tubing was merely used as a membrane. The tubing was soaked in water before applying and it was applied after the glucose oxidase was coated on the platinum wires on the end of the silastic drum. The membrane was stretched over the edge and then tied in place with many turns of silk thread. An important part of the process was to coat the 9 strands of platinum iridium wire with the enzyme glucose oxidase which was obtained from the Sigma Chemical Co., St. ~ouis, MO as a frozen powder identi-fied by catalog No. G-2133 which was a crystalline glucose oxidase, a bright yellow powder, mixed in equal quantity with gluconic acid as a preservative.
Glucose oxidase, where the gluconic acid had been removed by dialysis and freeze dried, may also be used. The glucose oxidase powder was simply dissolved in water to make a concentrated mixture and then spread over the wire. Then, as mentioned above, the cellulose membrane was pulled down over the enzyme coated platinum iridium wire. Thereafter, the entlre sensor was put in the vapor phase created from about 25~ aqueous glutaraldehyde overnight in a glass chamber wherein the glutaraldehyde was poured in the bottom of this closed glass chamber. The sensor, after treatment with the glutaraldehyde vapor which served to immobilize and insolubilize the enzyme, was removed and tested in a stirred cuvet containing phosphate buffered 7.4 and equilibrated or bubbled with air. The measurements were made at a temperature of about 40C. Such an electroenzymatic electrode was suitable as an implantable electrode or for use with undiluted, whole blood as a dipping electrode. In the implanted sensor following this procedure of calibra-tion where increasing amounts of glucose were added to the stirred buffer, the glucose sensor was stored in 70% alcohol in the cold in the refrigerator until implanted in an animal.
Example 2 In Fig. 2 are shown cyclic in vitro polaro-grams generated by the electroenzymatic glucose sensor described in Example 1 which measured changing glucose concentrations in a thermostated cuvet which contained Gomori buffer. The PO2 Of the Gomori buffer was first brought near zero by bubbling nitrogen therethrough.
Then glucose was added, first to make~it 200 mg%, then 400 mg%. The current response (lower left quadrant) shows that the oxygen supply (upper right quadrant) was ade~uate and had to come from inside the closed container of the sensor.
Example 3 In Figs. 3a and 3b exemplify cyclic in vitro polarograms that can be generated with an electro-enzymatic sensor of this invention reflecting changing glucose concentrations in a thermostated cuvet con-taining Gomori buffer. The PO2 Of the Gomori buffer is first brought near zero by bubbling nitrogen therethrough. The glucose is then added, first to make it 200 mg%, then 400mg% as illustrated in Fig.
3a.
Thereafter, the same device can be used to detect changing glucose concentrations in undiluted, fresh whole goat blood as shown in Fig. 3b. It should be noted that in both Figs. 3a and 3b, the P02 does not decrease (upper right quadrant) as the glucose is increased. Thus, the current responses llower left quadrant) show that the oxygen supply ~upper right quadrant) is adequate in both the Gomori buffer solution and the undiluted, fresh whole goat's blood, and the oxygen comes from the chamber of the sensor at least in the case of the Gomori buffer, as depicted in Figs. 3a and 3b.
The present invention may, of course, be carried out in other specific ways than those herein set forth without departing from the spirit and essential characteristics of the invention. The present embodiment~ are, therefore, to be considered in all respects as illustrative and not restrictive and any change~ coming within the meaning and equivalency range of the appended claims are to be embraced therein.
~.
1~ =c~ = 2 , .,~ ~1 0 ~ o _ x ~ C ~ C c E ~ c o ~c ~ q x ~ ~ c cJ o u ~ ~ o O ~ a 3 ~ q o ~ ~ `X , ~ ~a ~ E ~ ~ ~ o e u O~ ~ O J Z t~ N ~ ~ E ~:1 0 Cl~
,~ ~U'0 o ~ - ~ o 9 U t~ o o'~ C O 3 ~
~ ~ ~ 8 ~ c c al ~ ~ ~ _, ~ ~ ~ ~r u~ ~ ~
, . , ,, ~ ~ , . _, , ~ ,o N C C
~ o x ~ ~ o e ~ o _ _ o ,' ~ , ~
.. .. ~
, u Z
C C ~ ~ o o C ..
U ~ C ~ U
."
~ ~ C ~ ~ ~ ~ ~ o o ~. o ~ ~ .. ~ ~"
~ c . . ~ o u u o ~ ~ ~ ~ ~ ~ 8 ~ ~ o Q :~ ~ ~ U
E G~ - ~ _ c 3` 31 X U I t~ E O a~
I Q, ~ V I I I I ~_ ¢ I ' I ~- I
z ~n la C n~ o Q ~ c~-l `' z ~ U z 2, ~ ~:
o C U ~o J tO ~ ~ U L~ ~
o ~ o ~ 0 a~ t`~ o N ~
Z _ ~
~o ~ 'U ~ 0 N 3 ~ o x ~ ~ ~
,. ,. ~ o o ~ o ~
S ~ ~ U C o ¢ U
It is also contemplated herein to incorpo-rate into, on or near the enclosed chamber 6, an electrolytic device or means for generating oxygen independent of the environment adjacent the device for independently generating or replenishing the reservoir of oxygen in the chamber. Such a device or means may be a small battery (not shown) attached on, near or inside chamber 6 for generating oxygen inside the chamber, or an oxygen generating cell ~not depicted) comprising phosphoric acid which becomes exposed to electrolyzed water from dissolved water vapor inside chamber 6 to produce oxygen. Oxygen from the electrolysis diffuses toward the sensor while hydrogen is preferred to difuse away from the sensor towards the body arrangeable by design of the electrolyte cell in the drum.
An electroenzymatic glucose sensor and an exemplary use thereof in accordance with the present invention will now be further illustrated by reference to the following examples.
ExamPle 1 A typical electroenzymatic sensor in accor-dance with this invention has been prepared as follows.
The drum was prepared from a piece of Dow Corning silastic tubing 0.1875 inches I.D. X 0.3125 inches O.D. A piece of about one centimeter was cut from this tubing and then on each end of the tubing was cemented to silastic sheeting using Dow Corning s~
silastic medical adhesive silicone type catalog No.
891 g}ue. The silastic sheeting or membrane was made by the Dow Corning Company and a one centimeter diameter circle of 0.010 inch thick material was cut.
The drum head was placed on both ends of the silastic tubing to form an enclosed drum. The wire used was MedWire Corp. platinum-iridium consisting of 9 strands of 0.0011 inch wire insulated with Teflon. A distance of about five millimeters of this wire's insulation was cut exposing the 9 strands of wire which were spread out across the surface of the drum. The wire was then put in 0.025 inches I.D. x 0.047 inches O.D.
silastic tubing and fastened to the edge of the tubing using silk thread. Then over the end of the elec-trode, where the platinum iridium wire had been spreadout, was placed a piece of regenerated cellulose membrane which was porous to glucose. The type found most useful was that called Spectropor and this was tubing made for dialysis and was made by the ~Jiscos process. When inflated, dialyzer tubing obtained from Arthur H. Thomas Co., Philadelphia, PA which has catalog No. 3787-F45, one and a quarter inch in diameter was used. Such tubing was merely used as a membrane. The tubing was soaked in water before applying and it was applied after the glucose oxidase was coated on the platinum wires on the end of the silastic drum. The membrane was stretched over the edge and then tied in place with many turns of silk thread. An important part of the process was to coat the 9 strands of platinum iridium wire with the enzyme glucose oxidase which was obtained from the Sigma Chemical Co., St. ~ouis, MO as a frozen powder identi-fied by catalog No. G-2133 which was a crystalline glucose oxidase, a bright yellow powder, mixed in equal quantity with gluconic acid as a preservative.
Glucose oxidase, where the gluconic acid had been removed by dialysis and freeze dried, may also be used. The glucose oxidase powder was simply dissolved in water to make a concentrated mixture and then spread over the wire. Then, as mentioned above, the cellulose membrane was pulled down over the enzyme coated platinum iridium wire. Thereafter, the entlre sensor was put in the vapor phase created from about 25~ aqueous glutaraldehyde overnight in a glass chamber wherein the glutaraldehyde was poured in the bottom of this closed glass chamber. The sensor, after treatment with the glutaraldehyde vapor which served to immobilize and insolubilize the enzyme, was removed and tested in a stirred cuvet containing phosphate buffered 7.4 and equilibrated or bubbled with air. The measurements were made at a temperature of about 40C. Such an electroenzymatic electrode was suitable as an implantable electrode or for use with undiluted, whole blood as a dipping electrode. In the implanted sensor following this procedure of calibra-tion where increasing amounts of glucose were added to the stirred buffer, the glucose sensor was stored in 70% alcohol in the cold in the refrigerator until implanted in an animal.
Example 2 In Fig. 2 are shown cyclic in vitro polaro-grams generated by the electroenzymatic glucose sensor described in Example 1 which measured changing glucose concentrations in a thermostated cuvet which contained Gomori buffer. The PO2 Of the Gomori buffer was first brought near zero by bubbling nitrogen therethrough.
Then glucose was added, first to make~it 200 mg%, then 400 mg%. The current response (lower left quadrant) shows that the oxygen supply (upper right quadrant) was ade~uate and had to come from inside the closed container of the sensor.
Example 3 In Figs. 3a and 3b exemplify cyclic in vitro polarograms that can be generated with an electro-enzymatic sensor of this invention reflecting changing glucose concentrations in a thermostated cuvet con-taining Gomori buffer. The PO2 Of the Gomori buffer is first brought near zero by bubbling nitrogen therethrough. The glucose is then added, first to make it 200 mg%, then 400mg% as illustrated in Fig.
3a.
Thereafter, the same device can be used to detect changing glucose concentrations in undiluted, fresh whole goat blood as shown in Fig. 3b. It should be noted that in both Figs. 3a and 3b, the P02 does not decrease (upper right quadrant) as the glucose is increased. Thus, the current responses llower left quadrant) show that the oxygen supply ~upper right quadrant) is adequate in both the Gomori buffer solution and the undiluted, fresh whole goat's blood, and the oxygen comes from the chamber of the sensor at least in the case of the Gomori buffer, as depicted in Figs. 3a and 3b.
The present invention may, of course, be carried out in other specific ways than those herein set forth without departing from the spirit and essential characteristics of the invention. The present embodiment~ are, therefore, to be considered in all respects as illustrative and not restrictive and any change~ coming within the meaning and equivalency range of the appended claims are to be embraced therein.
~.
Claims (45)
1. A device for sensing a product or reactant of an enzyme reaction with an analyte as a measure of the analyte comprising a gas permeable membrane having opposed sides, an enzyme on one side of said membrane for enzymatic reaction with the analyte in presence of oxygen to provide the product or reactant, a closed container for containing oxygen on the opposite side of said membrane to supply oxygen through said membrane for the enzymatic reaction, and means for sensing the product or reactant as a function of the analyte.
2. A device of claim 1 further comprising an analyte permeable membrane overlying said enzyme for allowing the analyte to permeate therethrough to supply the analyte for the enzymatic reaction.
3. A device of claim 2 wherein said analyte permeable membrane comprises cellulose.
4. A device of claim 1 wherein said sensing means is an electrical sensor or an optical sensor.
5. The device of claim 4 wherein said sensor is adapted to sense hydrogen peroxide as a measure of the analyte.
6. A device of claim 4 wherein said electrical sensor is a platinum anode in contact with said enzyme for electrolytically sensing the product or reactant from the enzymatic reaction.
7. A device of claim 4 wherein said optical sensor comprises an optical substance in contact with said enzyme for optical reaction with the product or reactant from the enzymatic reaction and a fiber optic for sensing the optical reaction which functions as a measure of the analyte.
8. A device of claim 7 wherein said optical substance is selected from the class consisting of a chromatic dye and a fluorescent dye.
9. A device of claim 1 wherein said membrane comprises an organosilicone polymer.
10. A device of claim 1 wherein said enzyme is selected from the class consisting of oxygen oxido-reductases.
11. A device of claim 1 wherein said closed container has a wall structure defining a hollow interior adapted for containing oxygen wherein said gas permeable membrane comprises at least a portion of the wall structure.
12. A device of claim 11 wherein said container is gas permeable and liquid impermeable.
13. A device of claim 11 wherein said container is permeable to oxygen.
14. A device of claim 13 wherein said container comprises an organo-silicone polymer.
15. A device of claim 1 wherein said container is adapted to extract oxygen from animal tissue adjacent thereto.
16. A device of claim 1 wherein said container comprises additional means for generating oxygen for supplying oxygen through said membrane for the enzymatic reaction.
17. A device of claim 1 wherein said container contains an oxygen transport substance.
18. A device of claim 17 wherein said oxygen transport substance is a perfluorocarbon or derivative thereof.
19. A device of claim 18 wherein said perfluoro-carbon or derivative thereof is a perfluorocyclocarbon.
20. A device for sensing a product or reactant of an enzyme reaction with an analyte in presence of oxygen which functions as a measure of the analyte comprising an enclosed chamber adapted for containing oxygen comprising a wall structure defining a hollow interior and having an external surface wherein at least a portion of the external surface has the enzyme associated therewith for the enzymatic reaction, the wall structure being adapted for allowing oxygen to permeate therethrough to supply oxygen for the enzymatic reaction, an analyte permeable membrane overlying the enzyme and connected to said chamber for allowing the analyte to permeate therethrough to supply the analyte for the enzymatic reaction, and means for sensing the product or reactant of the enzymatic reaction which functions as a measure of the analyte.
21. A device of claim 20 wherein said chamber is gas permeable and liquid impermeable.
22. A device of claim 20 wherein said chamber comprises an organosilicone polymer.
23. A device of claim 20 wherein the enzyme is selected from the class consisting of oxygen oxido-reductases.
24. A device of claim 20 wherein said analyte permeable membrane comprises cellulose.
25. A device of claim 20 wherein said sensing means is an electrical means or an optical means.
26. The device of claim 20 wherein said sensor is adapted to sense hydrogen peroxide as a measure of the analyte.
27. A device of claim 25 wherein said electrical means is a platinum anode in contact with the enzyme for electrolytically sensing the product or reactant of the enzymatic reaction.
28. A device of claim 25 wherein said optical means comprises an optical substance in contact with the enzyme for optical reaction with the generated product or reactant of the enzymatic reaction and a fiber optic for sensing the optical reaction which functions as a measure of the analyte.
29. A device of claim 28 wherein the optical substance is selected from the class consisting of a chromatic dye and a fluorescent dye.
30. A device of claim 20 wherein said chamber further contains an oxygen transporting substance.
31. A device of claim 30 wherein said oxygen transporting substance is a perfluorocarbon or deriva-tive thereof.
32. A device of claim 31 wherein the perfluoro-carbon or derivative thereof is a perfluorocyclocarbon.
33. A device of claim 20 wherein said chamber is adapted to extract oxygen from animal tissue adjacent thereto.
34. A device of claim 20 wherein said chamber includes additional means for generating oxygen for permeating through the wall structure to supply oxygen for the enzymatic reaction.
35. An electroenzymatic glucose device for sensing hydrogen peroxide generated from an enzymatic reaction of glucose and glucose oxidase in presence of oxygen which functions as a measure of glucose com-prising an enclosed organosilicone polymer chamber adapted for containing oxygen comprising a wall structure defining a hollow interior and having an external surface, glucose oxidase contiguous with at least a portion of the external surface for the enzymatic reaction, the wall structure of said chamber being adapted for allowing oxygen present in said chamber to permeate therethrough to said glucose oxidase for the enzymatic reaction, a cellulose membrane overlying said glucose oxidase and connected to said chamber for allowing glucose to permeate therethrough to said glucose oxidase for the enzymatic reaction, and a platinum anode in contact with the glucose oxidase for electrolytically sensing hydrogen peroxide generated from the enzymatic reaction which functions as a measure of the glucose.
36. A device of claim 35 wherein said chamber further contains an oxygen transporting substance.
37. A device of claim 36 wherein said oxygen transporting substance is a perfluorocarbon or deriva-tive thereof.
38. A device of claim 37 wherein said perfluoro-carbon or derivative thereof is a perfluorocyclocarbon.
39. A device of claim 35 wherein said chamber is adapted to extract oxygen from animal tissue located adjacent thereto.
40. A device of claim 35 wherein said chamber includes additional means for generating oxygen for permeating through the wall structure to supply oxygen for the enzymatic reaction.
41. A method of sensing a product or reactant of an enzyme reaction with an analyte as a measure of the analyte comprising providing a gas permeable membrane having opposed sides, providing an enzyme on one side of the membrane for enzymatic reaction with the analyte in presence of oxygen to generate the product or reactant, providing a closed container containing oxygen on the opposite side of the membrane to supply oxygen through the membrane for the enzymatic reac-tion, and sensing the product or reactant which func-tions as a measure of the analyte.
42. A method of claim 41 further providing an analyte permeable membrane over the enzyme for allowing the analyte to permeate therethrough to supply the analyte for the enzymatic reaction.
43. A method of claim 41 wherein said sensing is conducted with an electrical or optical sensor.
44. A method of claim 41 further providing a gas transporting agent within the container.
45. A method of claim 41 further providing additional means for generating oxygen inside the container for the enzymatic reaction.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US777,234 | 1985-09-18 | ||
US06/777,234 US4680268A (en) | 1985-09-18 | 1985-09-18 | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1284454C true CA1284454C (en) | 1991-05-28 |
Family
ID=25109668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000516055A Expired - Lifetime CA1284454C (en) | 1985-09-18 | 1986-08-15 | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
Country Status (6)
Country | Link |
---|---|
US (2) | US4680268A (en) |
EP (1) | EP0215678B1 (en) |
JP (1) | JP2638593B2 (en) |
AT (1) | ATE86307T1 (en) |
CA (1) | CA1284454C (en) |
DE (1) | DE3687871T2 (en) |
Families Citing this family (304)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8512796D0 (en) * | 1985-05-21 | 1985-06-26 | Bellhouse Brian John | Testing liquids |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
DE3614821A1 (en) * | 1986-05-02 | 1987-11-05 | Siemens Ag | IMPLANTABLE, CALIBRABLE MEASURING DEVICE FOR A BODY SUBSTANCE AND CALIBRATION METHOD |
JPS636451A (en) * | 1986-06-27 | 1988-01-12 | Terumo Corp | Enzyme sensor |
DE3806955A1 (en) * | 1987-03-03 | 1988-09-15 | Res Ass Bio Tech Chem | Glucose-sensitive FET sensor, and method for its fabrication |
US4974929A (en) * | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
US4830011A (en) * | 1987-09-30 | 1989-05-16 | Lim Shun P | Catheter tip polarographic lactic acid and lactate sensor for extended use in vivo |
JP2774343B2 (en) | 1988-06-23 | 1998-07-09 | アソシエイツ オブ ケイプ コード、インコーポレイテッド | Endotoxin binding proteins and uses thereof |
AT390517B (en) * | 1988-08-04 | 1990-05-25 | Avl Verbrennungskraft Messtech | OPTICAL SENSOR AND METHOD FOR THE PRODUCTION THEREOF |
US5200051A (en) * | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US6306594B1 (en) | 1988-11-14 | 2001-10-23 | I-Stat Corporation | Methods for microdispensing patterened layers |
US5250419A (en) * | 1988-12-16 | 1993-10-05 | L'oreal | Method for the direct measurement of at least one chemical parameter of skin using a biosensor |
US4953552A (en) * | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
IT1231916B (en) * | 1989-05-29 | 1992-01-15 | Ampliscientifica S R L | WEARABLE ARTIFICIAL PANCREAS |
US5109850A (en) * | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
US5250439A (en) * | 1990-07-19 | 1993-10-05 | Miles Inc. | Use of conductive sensors in diagnostic assays |
US5202261A (en) * | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
JPH05317294A (en) * | 1992-05-18 | 1993-12-03 | Matsushita Electric Ind Co Ltd | Ion sensor |
US5328823A (en) * | 1992-11-27 | 1994-07-12 | American Air Liquide | Enzyme-based biosensors for detecting noble gases |
US5341805A (en) * | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
DE4401400A1 (en) * | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
US5560356A (en) * | 1994-02-23 | 1996-10-01 | Vitrophage, Inc. | Diagnostic system and method using an implanted reflective device |
US5605152A (en) * | 1994-07-18 | 1997-02-25 | Minimed Inc. | Optical glucose sensor |
US5590651A (en) * | 1995-01-17 | 1997-01-07 | Temple University - Of The Commonwealth System Of Higher Education | Breathable liquid elimination analysis |
US6329139B1 (en) | 1995-04-25 | 2001-12-11 | Discovery Partners International | Automated sorting system for matrices with memory |
US5611900A (en) * | 1995-07-20 | 1997-03-18 | Michigan State University | Microbiosensor used in-situ |
US6766183B2 (en) | 1995-11-22 | 2004-07-20 | Medtronic Minimed, Inc. | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
US5711861A (en) * | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
US6002954A (en) * | 1995-11-22 | 1999-12-14 | The Regents Of The University Of California | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
AU1058297A (en) * | 1995-11-22 | 1997-06-11 | Minimed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
US6136274A (en) * | 1996-10-07 | 2000-10-24 | Irori | Matrices with memories in automated drug discovery and units therefor |
AU5446098A (en) * | 1996-11-21 | 1998-06-10 | Lawrence Livermore National Laboratory | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
US5964993A (en) * | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
NO311817B1 (en) * | 1996-12-23 | 2002-01-28 | Lifecare As | Method for recording the changes in the level of an osmotically active component in body fluid and device for carrying out the method |
US5914026A (en) * | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
SE9700384D0 (en) * | 1997-02-04 | 1997-02-04 | Biacore Ab | Analytical method and apparatus |
ATE227844T1 (en) | 1997-02-06 | 2002-11-15 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
US9155496B2 (en) * | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US6246893B1 (en) | 1997-06-12 | 2001-06-12 | Tecmed Incorporated | Method and device for glucose concentration measurement with special attention to blood glucose determinations |
US6081736A (en) | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
US6893552B1 (en) | 1997-12-29 | 2005-05-17 | Arrowhead Center, Inc. | Microsensors for glucose and insulin monitoring |
US6306347B1 (en) | 1998-01-21 | 2001-10-23 | Bayer Corporation | Optical sensor and method of operation |
US6254831B1 (en) | 1998-01-21 | 2001-07-03 | Bayer Corporation | Optical sensors with reflective materials |
US6190612B1 (en) | 1998-01-21 | 2001-02-20 | Bayer Corporation | Oxygen sensing membranes and methods of making same |
US6103033A (en) * | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6134461A (en) * | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US20020091324A1 (en) * | 1998-04-06 | 2002-07-11 | Nikiforos Kollias | Non-invasive tissue glucose level monitoring |
US6721582B2 (en) | 1999-04-06 | 2004-04-13 | Argose, Inc. | Non-invasive tissue glucose level monitoring |
US6505059B1 (en) | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US7899518B2 (en) * | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
WO1999053301A1 (en) * | 1998-04-14 | 1999-10-21 | The Regents Of The University Of California | Sensor probe for determining hydrogen peroxide concentration and method of use thereof |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6207110B1 (en) | 1998-08-21 | 2001-03-27 | Bayer Corporation | Metallic overcoating as a light attenuating layer for optical sensors |
US6107083A (en) * | 1998-08-21 | 2000-08-22 | Bayer Corporation | Optical oxidative enzyme-based sensors |
US6251260B1 (en) | 1998-08-24 | 2001-06-26 | Therasense, Inc. | Potentiometric sensors for analytic determination |
US6330464B1 (en) * | 1998-08-26 | 2001-12-11 | Sensors For Medicine & Science | Optical-based sensing devices |
US6304766B1 (en) | 1998-08-26 | 2001-10-16 | Sensors For Medicine And Science | Optical-based sensing devices, especially for in-situ sensing in humans |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
EP1192269A2 (en) | 1999-06-18 | 2002-04-03 | Therasense, Inc. | MASS TRANSPORT LIMITED i IN VIVO /i ANALYTE SENSOR |
US6370407B1 (en) | 1999-07-27 | 2002-04-09 | Tecmed, Incorporated | System for improving the sensitivity and stability of optical polarimetric measurements |
US6343225B1 (en) * | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
US6682938B1 (en) | 1999-09-15 | 2004-01-27 | The Regents Of The University Of California | Glucose sensing molecules having selected fluorescent properties |
US6673625B2 (en) | 1999-09-15 | 2004-01-06 | The Regents Of The University Of California | Saccharide sensing molecules having enhanced fluorescent properties |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US8012500B2 (en) * | 2000-01-01 | 2011-09-06 | Beta-O2 Technologies Ltd. | Implantable device |
IL134009A (en) * | 2000-01-12 | 2011-07-31 | Bo2 Technologies Ltd | Implantable device |
US6770322B1 (en) | 2000-03-03 | 2004-08-03 | Ysi Incorporated | Method of making a platform for use in a sensor in a microfluidic device |
US6551496B1 (en) | 2000-03-03 | 2003-04-22 | Ysi Incorporated | Microstructured bilateral sensor |
AUPQ937100A0 (en) * | 2000-08-15 | 2000-09-07 | Food & Packaging Centre Management Limited | Odour sensor |
US6560471B1 (en) * | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
WO2002066986A2 (en) * | 2001-02-15 | 2002-08-29 | Medtronic Minimed, Inc. | Polymers functionalized with fluorescent boronate motifs |
EP1397068A2 (en) | 2001-04-02 | 2004-03-17 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
DE10119036C1 (en) * | 2001-04-18 | 2002-12-12 | Disetronic Licensing Ag | Immersion sensor for measuring the concentration of an analyte using an oxidase |
CA2445127C (en) * | 2001-05-04 | 2011-12-13 | Sensors For Medicine And Science, Inc. | Electro-optical sensing device with reference channel |
US6549796B2 (en) | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US7166208B2 (en) * | 2004-03-03 | 2007-01-23 | Stephen Eliot Zweig | Apoenzyme reactivation electrochemical detection method and assay |
US8506550B2 (en) * | 2001-09-07 | 2013-08-13 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US7045361B2 (en) | 2001-09-12 | 2006-05-16 | Medtronic Minimed, Inc. | Analyte sensing via acridine-based boronate biosensors |
US8465466B2 (en) * | 2001-10-23 | 2013-06-18 | Medtronic Minimed, Inc | Method and system for non-vascular sensor implantation |
US6923936B2 (en) * | 2001-10-23 | 2005-08-02 | Medtronic Minimed, Inc. | Sterile device and method for producing same |
US6814845B2 (en) | 2001-11-21 | 2004-11-09 | University Of Kansas | Method for depositing an enzyme on an electrically conductive substrate |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7470518B2 (en) | 2002-02-12 | 2008-12-30 | Cellectricon Ab | Systems and method for rapidly changing the solution environment around sensors |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
AU2003205132A1 (en) | 2002-02-12 | 2003-09-04 | Celectricon AB | Systems and methods for rapidly changing the solution environment around sensors |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7736309B2 (en) * | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
US20040181343A1 (en) * | 2002-11-01 | 2004-09-16 | Cellectricon Ab | Computer program products and systems for rapidly changing the solution environment around sensors |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
AU2003303597A1 (en) | 2002-12-31 | 2004-07-29 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7875293B2 (en) * | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US8066639B2 (en) * | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US20050051427A1 (en) * | 2003-07-23 | 2005-03-10 | Brauker James H. | Rolled electrode array and its method for manufacture |
JP2007500336A (en) * | 2003-07-25 | 2007-01-11 | デックスコム・インコーポレーテッド | Electrode system for electrochemical sensors |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2005019795A2 (en) * | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7519408B2 (en) | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7933639B2 (en) | 2003-08-01 | 2011-04-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7276029B2 (en) * | 2003-08-01 | 2007-10-02 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7494465B2 (en) | 2004-07-13 | 2009-02-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20100168657A1 (en) * | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US20050090607A1 (en) * | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
EP2239567B1 (en) | 2003-12-05 | 2015-09-02 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP3175780A1 (en) * | 2003-12-18 | 2017-06-07 | Metronom Health, Inc. | Implantable biosensor and methods of use thereof |
US7637868B2 (en) * | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
US20050182451A1 (en) * | 2004-01-12 | 2005-08-18 | Adam Griffin | Implantable device with improved radio frequency capabilities |
BRPI0507376A (en) | 2004-02-06 | 2007-07-10 | Bayer Healthcare Llc | oxidizable species as an internal reference for biosensors and method of use |
US7364592B2 (en) * | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
EP1718198A4 (en) | 2004-02-17 | 2008-06-04 | Therasense Inc | Method and system for providing data communication in continuous glucose monitoring and management system |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8277713B2 (en) * | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) * | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP1759536B1 (en) | 2004-06-01 | 2011-05-18 | Kwalata Trading Limited | In vitro techniques for use with stem cells |
US20060015020A1 (en) * | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
US20060020192A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP1786834B1 (en) | 2004-07-14 | 2016-02-17 | Glusense Ltd. | Implantable power sources and sensors |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US20110190603A1 (en) * | 2009-09-29 | 2011-08-04 | Stafford Gary A | Sensor Inserter Having Introducer |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US8571624B2 (en) | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US20070027381A1 (en) * | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US20110060196A1 (en) * | 2009-08-31 | 2011-03-10 | Abbott Diabetes Care Inc. | Flexible Mounting Unit and Cover for a Medical Device |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US20110054275A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Mounting Unit Having a Sensor and Associated Circuitry |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US20060249381A1 (en) * | 2005-05-05 | 2006-11-09 | Petisce James R | Cellulosic-based resistance domain for an analyte sensor |
WO2006110193A2 (en) * | 2005-04-08 | 2006-10-19 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US7308292B2 (en) | 2005-04-15 | 2007-12-11 | Sensors For Medicine And Science, Inc. | Optical-based sensing devices |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
CN103558284B (en) * | 2005-07-20 | 2017-04-12 | 安晟信医疗科技控股公司 | Gated amperometry |
US7799573B2 (en) * | 2005-08-31 | 2010-09-21 | Normadics, Inc. | Detection of explosives and other species |
CN101273266B (en) * | 2005-09-30 | 2012-08-22 | 拜尔健康护理有限责任公司 | Gated voltammetry |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US20090054747A1 (en) * | 2005-10-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and system for providing analyte sensor tester isolation |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
CA2636034A1 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care Inc. | Medical device insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
EP2004796B1 (en) * | 2006-01-18 | 2015-04-08 | DexCom, Inc. | Membranes for an analyte sensor |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
US7809441B2 (en) * | 2006-05-17 | 2010-10-05 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
US20090054749A1 (en) * | 2006-05-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and System for Providing Data Transmission in a Data Management System |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US20070287991A1 (en) * | 2006-06-08 | 2007-12-13 | Mckay William F | Devices and methods for detection of markers of axial pain with or without radiculopathy |
GB0616566D0 (en) * | 2006-08-19 | 2006-09-27 | Rolls Royce Plc | An alloy and method of treating titanium aluminide |
EP1892877B1 (en) * | 2006-08-25 | 2008-12-03 | Alcatel Lucent | Digital signal receiver with Q-monitor |
WO2008038274A1 (en) * | 2006-09-29 | 2008-04-03 | Medingo Ltd. | Fluid delivery system with electrochemical sensing of analyte concentration levels |
ES2825036T3 (en) * | 2006-10-24 | 2021-05-14 | Ascensia Diabetes Care Holdings Ag | Transient decay amperometry |
US20100047311A1 (en) * | 2006-11-22 | 2010-02-25 | Beta O2 Technologies Ltd. | Protecting algae from body fluids |
EP2104492B1 (en) * | 2006-11-28 | 2017-11-22 | Beta O2 Technologies Ltd. | Oxygen supply for cell transplant and vascularization |
US20080214912A1 (en) * | 2007-01-10 | 2008-09-04 | Glucose Sensing Technologies, Llc | Blood Glucose Monitoring System And Method |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
RU2444980C2 (en) * | 2007-03-07 | 2012-03-20 | Эко Терапьютикс, Инк. | Transdermal system of analite monitoring and methods of analite detection |
US8647579B2 (en) | 2007-03-19 | 2014-02-11 | Nomadics, Inc. | Hydrogen peroxide detector comprising light-blocking tip with air deflector |
EP2129285B1 (en) | 2007-03-26 | 2014-07-23 | Dexcom, Inc. | Analyte sensor |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US20080281179A1 (en) * | 2007-05-08 | 2008-11-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
EP2152350A4 (en) | 2007-06-08 | 2013-03-27 | Dexcom Inc | Integrated medicament delivery device for use with continuous analyte sensor |
US20080318314A1 (en) * | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
US9968742B2 (en) * | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
US8821431B2 (en) * | 2007-09-07 | 2014-09-02 | Beta O2 Technologies Ltd. | Air gap for supporting cells |
EP4098177A1 (en) | 2007-10-09 | 2022-12-07 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
US8320983B2 (en) | 2007-12-17 | 2012-11-27 | Palo Alto Research Center Incorporated | Controlling transfer of objects affecting optical characteristics |
EP2254458A1 (en) | 2008-02-04 | 2010-12-01 | Bayer HealthCare, LLC | Semiconductor based analyte sensors and methods |
US20090242399A1 (en) * | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9540630B2 (en) * | 2008-09-17 | 2017-01-10 | Beta O2 Technologies Ltd. | Optimization of alginate encapsulation of islets for transplantation |
US9446168B2 (en) | 2010-06-07 | 2016-09-20 | Beta-O2 Technologies Ltd. | Multiple-layer immune barrier for donor cells |
EP2326944B1 (en) | 2008-09-19 | 2020-08-19 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
WO2010033748A1 (en) | 2008-09-19 | 2010-03-25 | Bayer Healthcare Llc | Electrical devices with enhanced electrochemical activity and manufacturing methods thereof |
US8043271B2 (en) * | 2008-11-26 | 2011-10-25 | Beta 02 Technologies Ltd. | Apparatus for transportation of oxygen to implanted cells |
US20100160749A1 (en) * | 2008-12-24 | 2010-06-24 | Glusense Ltd. | Implantable optical glucose sensing |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US20100198034A1 (en) | 2009-02-03 | 2010-08-05 | Abbott Diabetes Care Inc. | Compact On-Body Physiological Monitoring Devices and Methods Thereof |
US20100213057A1 (en) | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
RU2489089C2 (en) * | 2009-03-16 | 2013-08-10 | АРКРЭЙ, Инк. | Method of continuous measurement of substrate concentration |
EP2410910A4 (en) | 2009-03-27 | 2014-10-15 | Dexcom Inc | Methods and systems for promoting glucose management |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9351677B2 (en) | 2009-07-02 | 2016-05-31 | Dexcom, Inc. | Analyte sensor with increased reference capacity |
EP2448485B1 (en) | 2009-07-02 | 2021-08-25 | Dexcom, Inc. | Analyte sensor |
WO2011025999A1 (en) * | 2009-08-29 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte sensor |
US20110106126A1 (en) * | 2009-08-31 | 2011-05-05 | Michael Love | Inserter device including rotor subassembly |
WO2011026147A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
WO2011041531A1 (en) | 2009-09-30 | 2011-04-07 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US8574510B2 (en) * | 2009-09-30 | 2013-11-05 | Bayer Healthcare Llc | Stackable electrochemical analyte sensors, systems and methods including same |
WO2011044386A1 (en) * | 2009-10-07 | 2011-04-14 | Abbott Diabetes Care Inc. | Sensor inserter assembly having rotatable trigger |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
CA3135001A1 (en) | 2010-03-24 | 2011-09-29 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US8702967B2 (en) | 2010-06-17 | 2014-04-22 | Bayer Healthcare Llc | Test strip with magneto-elastic-resonance sensor |
US9215995B2 (en) | 2010-06-23 | 2015-12-22 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
PL2637560T3 (en) | 2010-11-12 | 2017-06-30 | Ascensia Diabetes Care Holdings Ag | Temperature sensing analyte sensors, systems, and methods of manufacturing and using same |
WO2012142502A2 (en) | 2011-04-15 | 2012-10-18 | Dexcom Inc. | Advanced analyte sensor calibration and error detection |
US9037205B2 (en) | 2011-06-30 | 2015-05-19 | Glusense, Ltd | Implantable optical glucose sensing |
WO2013028596A1 (en) | 2011-08-24 | 2013-02-28 | Bayer Healthcare Llc | Analyte sensors and systems including retention tab and methods of manufacturing |
US9375684B2 (en) * | 2011-09-09 | 2016-06-28 | The University Of Kentucky Research Foundation | Green synthesis nanocomposite membranes |
JP6443802B2 (en) | 2011-11-07 | 2018-12-26 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Analyte monitoring apparatus and method |
EP4344633A2 (en) | 2011-12-11 | 2024-04-03 | Abbott Diabetes Care, Inc. | Analyte sensor methods |
US8808519B2 (en) * | 2011-12-14 | 2014-08-19 | Hamilton Sundstrand Space Systems International | Microfluidic device |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
TWI536021B (en) | 2013-03-11 | 2016-06-01 | 拜耳保健公司 | Strip grabber |
US9376708B2 (en) | 2013-03-13 | 2016-06-28 | Ascensia Diabetes Care Holdings Ag | Bottled glucose sensor with no handling |
EP2859911A1 (en) | 2013-10-11 | 2015-04-15 | qSTAR Medical SAS | Vascular access port devices with incorporated sensors |
US10575765B2 (en) | 2014-10-13 | 2020-03-03 | Glusense Ltd. | Analyte-sensing device |
WO2016183493A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
US10716500B2 (en) | 2015-06-29 | 2020-07-21 | Cardiac Pacemakers, Inc. | Systems and methods for normalization of chemical sensor data based on fluid state changes |
MX2018002587A (en) | 2015-09-02 | 2019-02-07 | Metronom Health Inc | Systems and methods for continuous health monitoring using an opto-enzymatic analyte sensor. |
US11432750B2 (en) * | 2016-03-14 | 2022-09-06 | Abbott Diabetes Care Inc. | In vivo enzyme activity sensors and methods |
US10871487B2 (en) | 2016-04-20 | 2020-12-22 | Glusense Ltd. | FRET-based glucose-detection molecules |
CN115444410A (en) | 2017-01-23 | 2022-12-09 | 雅培糖尿病护理公司 | Applicator and assembly for inserting an in vivo analyte sensor |
CN108968976B (en) | 2017-05-31 | 2022-09-13 | 心脏起搏器股份公司 | Implantable medical device with chemical sensor |
CN109381195B (en) | 2017-08-10 | 2023-01-10 | 心脏起搏器股份公司 | Systems and methods including electrolyte sensor fusion |
CN109419515B (en) | 2017-08-23 | 2023-03-24 | 心脏起搏器股份公司 | Implantable chemical sensor with staged activation |
DE102018216580A1 (en) * | 2017-09-27 | 2019-03-28 | University Of Cincinnati | Hydrogen sensitive layer and sensors made therefrom |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
WO2019103785A1 (en) * | 2017-11-27 | 2019-05-31 | Trustees Of Tufts College | Textile with optical dyes for sensing fluid-borne analytes |
CN109864746B (en) | 2017-12-01 | 2023-09-29 | 心脏起搏器股份公司 | Multimode analyte sensor for medical devices |
CN109864747B (en) | 2017-12-05 | 2023-08-25 | 心脏起搏器股份公司 | Multimode analyte sensor optoelectronic interface |
CA3142756A1 (en) * | 2020-12-16 | 2022-06-16 | Mcmaster University | System and method for detecting analytes in water |
CN114755402A (en) | 2021-01-11 | 2022-07-15 | 安晟信医疗科技控股公司 | Analyte meter, test strip ejector and method of using test strip ejector |
US20230145155A1 (en) * | 2021-10-29 | 2023-05-11 | Cercacor Laboratories, Inc. | Implantable micro-electrochemical cell |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2913386A (en) * | 1956-03-21 | 1959-11-17 | Jr Leland C Clark | Electrochemical device for chemical analysis |
US3380905A (en) * | 1963-10-11 | 1968-04-30 | Leland C. Clark Jr. | Electrolytic sensor with anodic depolarization |
US3539455A (en) * | 1965-10-08 | 1970-11-10 | Leland C Clark Jr | Membrane polarographic electrode system and method with electrochemical compensation |
US3577332A (en) * | 1967-07-12 | 1971-05-04 | Beckman Instruments Inc | Polarographic cell |
US3591480A (en) * | 1968-07-15 | 1971-07-06 | Ibm | Glucose measuring system |
US3911138B1 (en) * | 1973-02-26 | 1996-10-29 | Childrens Hosp Medical Center | Artificial blood and method for supporting oxygen transport in animals |
US3992158A (en) * | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US4245634A (en) * | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4040908A (en) * | 1976-03-12 | 1977-08-09 | Children's Hospital Medical Center | Polarographic analysis of cholesterol and other macromolecular substances |
US4151845A (en) * | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
JPS5921500B2 (en) * | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
US4458686A (en) * | 1979-08-02 | 1984-07-10 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
JPS5627643A (en) * | 1979-08-14 | 1981-03-18 | Toshiba Corp | Electrochemical measuring device |
US4403984A (en) * | 1979-12-28 | 1983-09-13 | Biotek, Inc. | System for demand-based adminstration of insulin |
SE419903B (en) * | 1980-03-05 | 1981-08-31 | Enfors Sven Olof | enzyme electrode |
US4313439A (en) * | 1980-03-24 | 1982-02-02 | Biotek, Inc. | Automated, spring-powered medicament infusion system |
US4368737A (en) * | 1980-07-07 | 1983-01-18 | Purdue Research Foundation | Implantable catheter |
US4378016A (en) * | 1981-07-15 | 1983-03-29 | Biotek, Inc. | Artificial endocrine gland containing hormone-producing cells |
US4402694A (en) * | 1981-07-16 | 1983-09-06 | Biotek, Inc. | Body cavity access device containing a hormone source |
JPS58171658A (en) * | 1982-04-02 | 1983-10-08 | Hitachi Ltd | Glucose analysis method |
US4443480A (en) * | 1982-04-12 | 1984-04-17 | Children's Hospital Medical Center | Artificial blood and other gas transport agents |
US4464230A (en) * | 1982-04-19 | 1984-08-07 | University Of Rhode Island | Method of measuring oxygen using a membrane covered polarographic electrode |
US4484987A (en) * | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
JPS6117948A (en) * | 1984-07-05 | 1986-01-25 | Fuji Electric Corp Res & Dev Ltd | Immobilized enzyme film for enzyme electrode |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
-
1985
- 1985-09-18 US US06/777,234 patent/US4680268A/en not_active Expired - Lifetime
-
1986
- 1986-08-15 CA CA000516055A patent/CA1284454C/en not_active Expired - Lifetime
- 1986-09-17 EP EP86307174A patent/EP0215678B1/en not_active Expired - Lifetime
- 1986-09-17 DE DE8686307174T patent/DE3687871T2/en not_active Expired - Lifetime
- 1986-09-17 AT AT86307174T patent/ATE86307T1/en not_active IP Right Cessation
- 1986-09-17 JP JP61219106A patent/JP2638593B2/en not_active Expired - Lifetime
-
1987
- 1987-05-07 US US07/047,013 patent/US4721677A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE3687871D1 (en) | 1993-04-08 |
US4721677A (en) | 1988-01-26 |
ATE86307T1 (en) | 1993-03-15 |
JP2638593B2 (en) | 1997-08-06 |
US4680268A (en) | 1987-07-14 |
EP0215678A2 (en) | 1987-03-25 |
JPS6287135A (en) | 1987-04-21 |
EP0215678B1 (en) | 1993-03-03 |
EP0215678A3 (en) | 1988-11-17 |
DE3687871T2 (en) | 1993-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1284454C (en) | Implantable gas-containing biosensor and method for measuring an analyte such as glucose | |
EP0154664B1 (en) | Measurement of body substances | |
US6893552B1 (en) | Microsensors for glucose and insulin monitoring | |
EP1214586B1 (en) | Implantable glucose sensor | |
Atanasov et al. | Biosensor for continuos glucose monitoring | |
EP0393054B1 (en) | A process and system and measuring cell assembly for glucose determination | |
Wilkins et al. | Integrated implantable device for long-term glucose monitoring | |
EP0206531B1 (en) | Electrochemical cell sensor for continuous, short-term use in tissues and blood | |
Laurell | A continuous glucose monitoring system based on microdialysis | |
Schoonen et al. | Development of a potentially wearable glucose sensor for patients with diabetes mellitus: design and in-vitro evaluation | |
CA1177735A (en) | Method of polarographic analysis of lactic acid and lactate | |
Clark Jr et al. | Implanted electroenzymatic glucose sensors | |
EP1786834B1 (en) | Implantable power sources and sensors | |
Vaidya et al. | Effect of interference on the performance of glucose enzyme electrodes using Nafion® coatings | |
Clark Jr et al. | [6] Long-term implantation of voltammetric oxidase/peroxide glucose sensors in the rat peritoneum | |
Rolfe | In vivo chemical sensors for intensive-care monitoring | |
Abel et al. | Stability of immobilized enzymes as biosensors for continuous application in vitro and in vivo | |
Santoni et al. | Enzyme electrode for glucose determination in whole blood | |
Vadgama et al. | Electrochemical transducers for in vivo monitoring | |
Von Woedtke et al. | Glucose oxidase electrodes: effect of hydrogen peroxide on enzyme activity? | |
WO1999039629A1 (en) | Chemical sensors having microflow systems | |
Vadgama et al. | In vivo biosensors | |
Gamburzev et al. | Performance of glucose biosensor based on oxygen electrode in physiological fluids and at body temperature | |
Atanasov et al. | Glucose Biosensor Based on Oxygen Electrode. Part II: Long-Term Operational Stability of the Rechargeable Glucose Biosensor | |
Jobnson et al. | Reduction of electrooxidizable interferent effects: Optimization of the applied potential for amperometric glucose sensors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed | ||
MKEC | Expiry (correction) |
Effective date: 20121205 |